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ABSTRACT 
TUMOR INTERFERON SIGNALING INITIATES AND SUSTAINS A MULTIGENIC 
RESISTANCE PROGRAM TO IMMUNE CHECKPOINT BLOCKADE  
Joseph L. Benci 
Andy J. Minn, M.D., Ph.D. 
 
Therapeutic blockade of the CTLA4 and/or PD1 immune checkpoint pathways has 
resulted in significant anti-tumor responses in broad variety of cancer types, but resistance 
is common. Using mouse models of metastatic melanoma and breast cancer in 
combination with CRISPR/Cas9 to selectively delete genes in our tumor cells, we 
demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-
independent resistance to immune checkpoint blockade (ICB), and to combinations such 
as radiation plus anti-CTLA4.  Furthermore, we show that this interferon driven resistance 
mechanism primarily occurs in ICB resistant tumors and not in ICB responsive tumors. 
Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic 
changes and augments expression of interferon-stimulated genes and ligands for multiple 
T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. 
Crippling the program genetically or pharmacologically interferes with multiple inhibitory 
pathways, and expands distinct T cell populations with improved anti-tumor functions 
despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-
agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that 
biomarkers for interferon-driven resistance associate with clinical progression after anti-
PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive 
resistance and inhibition of the interferon response bypasses requirements for 
combinatorial ICB therapies. 
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CHAPTER 1: Introduction 
 
Metastatic Disease is the Leading Cause of Cancer Related Mortality 
 
Cancers can be classified as primary, located only in a single tissue, or metastatic, 
having spread from that initial location to other nearby or even distant parts of the body.  
With few exceptions, primary cancers are non-lethal and are easily managed by some 
combination of radiation, chemotherapy, and/or surgical resection.  It is the disseminated, 
metastatic tumors that cause most cancer deaths.  It is estimated that over 90% of all 
cancer related deaths are due to metastatic not primary disease1.  Among the 6 most 
prevalent cancer types in the United States- Breast, Lung, Prostate, Colorectal, Bladder 
and Melanoma – the average five-year survival drops from an average of 85% in primary 
cancer to 16% in patients with metastatic disease2.  Early detection is one of the most 
important ways to improve survival by identifying a primary tumor before it has a chance 
to metastasize. 
Diagnostic technology has made significant advancements in the last thirty years.  
Imaging modalities such as computed tomography (CT) and magnetic resonance imaging 
(MRI) can slice patients into millimeter thick slices, allowing for increasingly early detection 
of cancerous growths.  However, the enhanced diagnostic sensitivity also alters the 
natural course of the disease3.  Improved imaging resolution creates a lead-time bias 
where survival statistics, such as the previously mentioned 5-year survival rate, increase 
simply because of earlier detection, not because of any improvement in anti-cancer 
therapies.  Between 1950 and 1995, increases in five-year survivorship rates across 
twenty cancer types, as reported by the National Cancer Institute’s surveillance, 
epidemiology, and end results (SEER) program, had almost no correlation in changes with 
cancer mortality4.  This observation strongly suggests that improvements in five-year 
survival were due to lead-time bias from increased early detection, not through 
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improvements in cancer therapies.  Additionally, some of these lesions if left untreated 
may never even develop into clinical disease at all, a concept known as overdiagnosis5, 
thus improving survival statistics without changing disease outcome.   
Although aggressive screening creates a lead time bias, the benefits of improved 
screening for certain patient groups is undeniable.  Women with the inherited BRCA2 gene 
mutation have a 45% chance of developing breast cancer and an 11% chance of 
developing ovarian cancer by age 706.  In these high risk patients intensive screening 
using both yearly mammogram and MRI to increase early detection increase ten-year 
survival by 15% versus mammography alone7.  Survival benefits with intensive screening 
were also found in patients with a hereditary risk for pancreatic ductal adenocarcinoma.  
In these patients the five year survival rate was 24%, nearly four times higher than patients 
in the standard screening group8.  In genetically predisposed individuals the benefits of 
early and aggressive screening lead to significant survival benefits amongst multiple 
cancer types.  
One treatment modality which has significantly improved patient survival are a 
class of drugs known as targeted therapies.  Instead of being generally toxic to tumor cells 
the way traditional chemotherapies and radiation are, targeted therapies interact with and 
inhibit specific proteins within the tumor that are crucial for tumor proliferation and 
survival9.  Patients whose tumors rely on these druggable proteins derive significant 
benefit from these therapies compared to traditional therapies.  Targeted therapies against 
BRAF driven melanoma, HER-2 positive breast cancer, and BCR-ABL driven leukemia, 
as well as many other treatments significantly improve survival in patients whose tumors 
depend on these proteins.  However, many patient’s tumors do not have the required 
targets for the drugs and even those who do can develop compensatory mutations 
rendering the drugs ineffective.  With the limited efficacy of exogenous therapies, many 
showing only modest benefits against metastatic cancers, recent research has focused 
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on immunotherapy, marshalling the patient’s own immune system to fight the tumors has 
led to significant and durable therapeutic responses. 
Cancer Immunosurveillance 
 
The idea that the immune system could detect and eliminate nascent tumors was 
first proposed by Nobel Laureate Paul Ehrlich in 1909.  Nearly fifty years later Prehn and 
Main showed that carcinogen derived tumors could be rejected without any treatment 
when transplanted into naive mice, however spontaneously occurring tumors could not be 
rejected upon transplantation10, suggesting that these slow-to-develop spontaneous 
tumors had undergone a different form of tumorigenesis than the carcinogen derived 
tumors.  These observations formed the root of the cancer immunosurveillance hypothesis 
put forth by FM Burnet in 197011.  The cancer immunosurveillance hypothesis proposed 
that immune cells actively search for and eliminate transformed cells as they occurred 
throughout the body, and that without this surveillance the rate of all cancer types would 
be much higher at the population level than was observed.  Under this theory, clinically 
detectable tumors occurred when transformed cells escaped this immune elimination and 
grew larger thus forming clinically detectable tumors.  Though it would ultimately prove 
correct, the cancer immunosurveillance hypothesis hit an early road block.   
Nude mice are a common laboratory mouse strain harboring a genetic mutation 
which causes them to have a nearly-absent thymus and which at the time of Burnet’s 
paper were believed to completely lack T cells.  If the cancer immunosurveillance 
hypothesis was correct, nude mice should develop spontaneous tumors at a much higher 
frequency than wild-type mice and should be much more susceptible to carcinogen 
induced tumors.  However, in a head-to-head comparison nude mice did not either 
spontaneously or after exposure to carcinogens develop tumors at a higher frequency 
than wild-type mice, suggesting the cancer immunosurveillance hypothesis was wrong12.  
This seemingly definitive experiment would shelve Burnet’s theory for nearly thirty years 
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before better mouse models would lead to renewed interest in the role of the immune 
system in fighting cancer.  Interferon gamma (IFN gamma) or interferon gamma receptor 
knockout mice developed tumors faster and with greater frequency than wild-type 
mice13,14.  This suggested that IFN gamma was a central effector molecule in regulating 
the anti-tumor response in mice, not coincidentally IFN gamma is known as a critical 
mediator of T cell function15.  Further evidence for the role of the immune system in 
containing tumors came from the observation that mice lacking perforin, a protein used by 
immune cells to kill target cells, develop B cell lymphomas at a high frequency16.  
Transplanting these lymphomas into wild-type mice led to their rejection in a CD8+ T cell 
dependent manner, consistent with Burnet’s original immunosurveillance hypothesis.  
Finally, the development of the recombinant activating gene 1 (Rag1) knockout mice, 
which have no T cells, provided a better host mouse to test the immunosurveillance 
hypothesis.   
Burnet was vindicated by the finding that in these Rag1 KO mice, a significant 
fraction develop spontaneous lung and intestinal adenocarcinomas and they were also 
significantly more susceptible to carcinogen induced tumors than wild-type mice17.  Finally, 
nearly 100 years after Paul Ehrlich first proposed that the immune system could detect 
and eliminate tumors there was conclusive experimental proof this occurred in animals, 
and that it was T cell dependent.  Since then, the cancer immunosurveillance hypothesis 
has been extensively studied in mice and there is evidence this process occurs in humans 
as well.  An analysis of 30 years of solid organ transplant recipients from the US Scientific 
Registry of Transplant Recipients found a significantly increased risk of 32 different 
malignancies in immunosuppressed transplant recipients compared to the general 
population18.  The increased risk of cancer among these immunosuppressed transplant 
recipients mirrors the increased risk in Rag1 KO mice suggesting that the same 
mechanisms of tumor surveillance occur in humans as well as mice.   
5 
 
Multiple Immune Populations Mediate Tumor Rejection 
 
Consistent with Burnet’s hypothesis, the presence of CD8+ T cells in many tumor 
types has been shown to correlate with better response to multiple therapeutic modalities.  
An analysis of 109 stage II/III colon cancer patients found that amount of intratumoral 
cytotoxic CD8+ T cells by histology correlated with improved overall and disease-free 
survival in patients treated with either surgery alone or the combination of surgery and 
chemotherapy19.  Another study in colon cancer used RNA-sequencing to look for a 
cytotoxic T cell signature also found a correlation between the strength of this signature 
and a decreased incidence of recurrence post-surgery and improved overall survival20.  A 
meta-analysis of microarray data from over 2000 breast cancer patients found that in 
tumors with high expression of immune metagenes there was decreased risk of 
metastasis and increased overall survival21.  In ovarian cancer, over half of all tumor 
samples had T cells in the tumor, and patients with T cell rich tumors had a 5-year survival 
rate that was seven times higher than patients without a strong T cell infiltrate22.    Despite 
the focus of early pre-clinical researchers as well as many clinical papers on the ability of 
the cytotoxic T cells to kill cancer cells, many immune cells play a role in the anti-tumor 
response.  
Natural killer (NK) cells can directly eliminate tumor cells that downregulate class 
I MHC as a method of escaping T cell mediated immune surveillance23.  Much like Rag1 
KO mice developed tumors at an increased rate compared to wild-type mice, when dual 
Rag KO/Perforin knockout mice were implanted with a colorectal cancer cell line, the 
implanted tumors grew faster and developed an increased number of lung metastases 
comparted to Rag single knockout mice24.  This effect was NK cell dependent, showing 
that NK cells can contain nascent tumors and metastases much the same way T cells can.  
In mouse models of breast and lung cancer, NK cells were able to prolong tumor latency 
by eliminating cycling tumor cells25.  In vitro NK cells isolated from the blood of healthy 
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human donors were able to eliminate primary human melanoma cells treated with a sub-
apoptotic dose of doxorubicin suggesting that in patients, chemotherapy can synergize 
with immune cells to promote better tumor clearance26.   
An additional immune subset that plays an important role in tumor killing is 
dendritic cells (DCs).  DCs play an important role in bridging the innate immune response 
such as the non-specific killing of all MHC I low cells by NK cells and the highly specific 
adaptive immune response mediated by T cells27.  In vitro, DCs have been shown to 
phagocytose apoptotic tumor cells and cross-present tumor antigens to prime CD8+ T cells 
to better eliminate the tumor28.  Similar to T cells, the presence of dendritic cells in the 
tumor has been correlated with improved response to treatment and overall survival in 
several cancer types29,30.  There is currently a dendritic cell therapy, Sipuleucel-T, which 
takes a patient’s own dendritic cells, expands them ex vivo in culture with a tumor protein, 
and then infuses them back into the patient to prime an immune response.  This therapy 
has shown significant benefit in patients with metastatic prostate cancer31.    However, not 
all immune populations are anti-tumorigenic.   
Macrophages can have either pro- or anti-tumor functions depending on their 
polarization32.  In the minority of cases macrophages correlate with better anti-tumor 
response.  In a study of 50 patients with non-small cell lung cancer the M1 macrophage 
density in the tumor positively correlated with overall survival33.  However, in many cancer 
types patient prognosis is inversely correlated with tumor associated macrophage 
density34,35.  While the presence of macrophages in the tumor may be a double-edged 
sword, the majority of immune cells in the tumor play a role in  containing tumor growth 
and improving response to therapy as evidenced by the increased tumor incidence in 
immunocompromised mice and human patients13,17,18.  Given the immune systems’ ability 
to detect and eliminate tumors, why do otherwise immunocompetent patients develop 
cancer at all?   
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Immune Checkpoints: A Double-Edged Sword 
 
While the immune system plays a crucial role in protecting the host against 
pathogens and cancer, over activation can cause autoimmunity which can be just as life-
threatening36.  To protect against this, during T cell maturation cells that react to host 
proteins are deleted to prevent autoimmunity in a process known as thymic selection37.  
As a second line of defense against self-reactive T cells that escaped thymic selection, 
and as a method of downregulating the immune response after an infection, there are also 
inhibitory pathways hardwired into immune cells known as immune checkpoints38.  One of 
the most well studied immune checkpoints in the context of the anti-tumor response is 
cytotoxic T lymphocyte-associated molecule-4 (CTLA4). 
CTLA4 is expressed on T cells and competes with CD28 to bind CD80 and CD86 
on antigen presenting cells39.  CD28 binding with these two molecules provides a co-
stimulatory signal which enhances T cell proliferation, cytokine production, and survival 
while CTLA4 binding to either molecule provides an inhibitory signal40,41.  This balance of 
inhibitory and stimulatory signals balances the immune response and ensures that the T 
cells do not become aberrantly activated in the absence of a foreign antigen, preventing 
autoimmunity.  The crucial role for CTLA4 in preventing autoimmunity is evidenced by the 
fact that CTLA4 deficient mice develop fatal autoimmunity by 3-4 weeks of age42,43.  
Consistent with the need for CD80/CD86 co-stimulation for T cell activation, this lethal 
autoimmunity can be avoided by creating a CTLA4/CD80/CD86 triple knockout mouse44.  
It was initially observed that there was a preferential expansion of CD4+ T cells in CTLA4 
KO mice, and that depleting CD4+ T cells could delay the onset of autoimmunity however 
depleting CD8s did not, suggesting that CTLA4 was a critical regulator of CD4+ T cell 
function45.  Later subsetting of the CD4+ T cell population showed that the CTLA4 was 
mainly on regulatory CD4+ T cells (Tregs) which play a critical role in preventing 
autoimmunity and inflammation46.  Taken together, these results suggest that CTLA4 may 
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be turning off the T cell response that is so crucial in eliminating nascent tumors.  This 
was demonstrated over twenty years ago by Jim Allison who used a CTLA4 blocking 
antibody to promote tumor regression in a mouse model of colon carcinoma47.  This is one 
of the first papers to show the benefits of blocking an immune checkpoint to promote tumor 
clearance.   
While CTLA4 was one of the first immune checkpoints discovered, it is not the only 
one, nor is it the only one that has been shown to be important in cancer.  Programmed 
cell death protein 1 (PD1) is an inducible surface receptor expressed on activated CD4, 
CD8, NK, and B cells48.  When PD1 binds one of its ligands at the same time the T cell 
receptor or B cell receptor (TCR or BCR) is engaged it transduces an inhibitory signal that 
dephosphorylates the TCR or BCR blocking signal transduction.  There are two well 
characterized ligands for PD1, PD-L1 and PD-L249.  PD-L1 is ubiquitously expressed 
throughout the body and can be found on almost all lymphohematopoietic cells and in 
most tissues of the body such as the heart, lungs, and kidneys50.  PD-L2 is more restricted 
in its expression and is primarily expressed in the liver.  Like CTLA4, the PD1 pathway 
functions to maintain peripheral tolerance and prevent aberrant killing of normal tissue 
during an immune response.  PD-L1 is upregulated in the placenta which mediates 
immune tolerance to the developing fetus, consistent with this inhibitory function, PD-L1 
knockout mice have a lower fetal survival rate than wild-type mice51.  Naïve dendritic cells 
that present antigens to CD8+ T cells express high levels of PD-L1 to ensure that without 
proper dendritic cell activation the T cells do not become activated, particularly against 
self-antigens52.  While not as drastic as the CTLA4 knockout mouse phenotype, PD1 
knockout mice also develop late-onset autoimmunity and cardiomyopathy53.  In addition 
to preventing accidental immune activation against self-antigens and autoimmunity, the 
PD1 pathway also serves to downregulate a correctly activated immune response after 
infection to prevent host tissue damage.  PD1 knockout mice clear an adenovirus infection 
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more quickly than wild-type mice but sustain more hepatocellular injury due to the 
persistence of activated T cells after viral clearance54.  However, too much PD1 signaling 
can allow viral infections to persist.  In HIV infected patients, higher PD1 expression on 
virus specific T cells is associated with worse disease progression55.  This double-edged 
sword of PD1 signaling, with too much early in the immune response preventing effective 
viral clearance, while not enough late in the response leading to tissue damage provides 
some insight into how the PD1 pathway may allow tumors to escape elimination by the 
immune system. 
PD-L1 expression on murine tumor cell lines increased their resistance to T cell 
mediated cytotoxicity and led to increased tumor growth in vivo56,57.   PD-L1 expressed on 
the tumor cells promotes T cell exhaustion, a functional state where the cell calls have 
reduced proliferative and functional capacity including diminished cytokine production and 
cytolytic activity crucial for killing tumor cells58.  Tumors genetically engineered to express 
soluble PD1 to bind up all the PD-L1 on the tumor surface were rejected at a significantly 
greater frequency than tumors just expressing PD-L1 that was free to bind PD1 on the 
immune cells59, suggesting that a PD1 or PD-L1 blocking antibody could be an effective 
anti-cancer therapy.  In renal cancer patients, PD1 expression on tumor infiltrating 
lymphocytes associates with worse outcome after radical nephrectomy than in patients 
with PD1 low TILs60.  PD1 expression correlated with an immune suppressive 
microenvironment and worse overall outcome in Hodgkin lymphoma as well61.  The 
presence of immune checkpoints in multiple tumor types implies that tumors escape 
immunosurveilance by taking advantage of these checkpoints to prevent elimination.  As 
Jim Allison’s work showed, using a blocking antibody against an immune checkpoint was 
an effective way to unleash the immune system against an established tumor suggesting 
this might be an effective clinical treatment47. 
Immune Checkpoint Blockade as a Cancer Therapy 
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The watershed moment for cancer immunotherapy came in 2010 after a clinical 
trial published in the New England Journal of Medicine showed significantly improved 
survival in patients with metastatic melanoma treated with a CTLA4 blocking antibody 
compared to the standard of care62.  Not only was the median survival better in the patients 
treated with anti-CTLA4 but about 20% completely cleared their tumor and remained 
cancer free for the duration of the study follow-up.  This study was closely followed by 
another trial comparing the combination of anti-CTLA4 and dacarbazine to dacarbazine 
alone.  Dual treated patients had higher overall survival and longer progression-free 
survival than patients treated with dacarbazine alone63. The results of this trial were so 
striking that in March 2011 the Food and Drug Administration granted broad approval for 
use of anti-CTLA4 in patients with metastatic melanoma either as a front-line therapy or 
for refractory patients.  Similar results were also observed in multiple other cancer types.  
Anti-CTLA4 combined with chemotherapy in advanced non-small cell lung cancer 
significantly improved overall survival versus chemotherapy alone64.  In patients with 
metastatic renal cancer anti-CTLA4 alone was sufficient to induce regression in 15% of 
patients65.   
While the clinical benefits of anti-CTLA4 in patients across a diverse array of 
cancer types is undeniable, the therapy is not without its downsides.  Nearly one-third of 
patients experience severe side effects over the course of therapy, and the treatment can 
take a long time to reduce the tumor burden, making it difficult to know whether patients 
should remain on the drug or be switched to a different treatment66.  While some patients 
did derive significant benefit from anti-CTLA4 many did not, suggesting that resistance 
could be occurring through additional immune checkpoints. 
Some patients with metastatic melanoma who progressed on anti-CTLA4, were 
able to get significant benefit from a clinical PD1 blocking antibody, suggesting this may 
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be one mechanism of resistance to anti-CTLA4 blockade67.  Even in patients who had not 
received previous treatment with anti-CTLA4, anti-PD1 lead to a significant improvement 
in overall survival versus dacarbazine68.  Responses to PD1 blockade were dramatic in 
several other cancer types as well including non-small cell lung cancer and Hodgkin 
lymphoma69,70.  Blocking PD-L1, the ligand for PD1 showed dramatic responses in several 
cancer types including metastatic bladder cancer71.  A head-to-head trial of anti-CTLA4 
and anti-PD1 in advanced metastatic melanoma showed PD1 blockade led to better 
overall survival and progression free survival than anti-CTLA472.  Since PD1 and CTLA4 
are distinct immune checkpoints, blocking both simultaneously could lead to better 
response than either one as a single agent therapy.  In one of the first trials looking at the 
combination of anti-CTLA4 and anti-PD1 in metastatic melanoma, 65% percent of patients 
responded, with over half having more than an 80% reduction in total tumor burden73.  
However, as the observations from CTLA4 and PD1 knockout mice would suggest, 
blocking multiple immune checkpoints can lead to serious side effects.  In another trial, 
over 60% of patients derived some benefit from the combination therapy however several 
died from treatment related toxicities74.  Combining a single immunotherapy with an 
additional therapy such as radiation is one potential avenue to maintain strong anti-tumor 
responses while reducing toxicity. 
Radiation can synergize with the immune system in several ways including 
promoting cytokine release, improving antigen presentation, and promoting a more anti-
tumorigenic microenvironment75.  Several preclinical reports indicate that radiation at a 
single tumor site could synergize with immune checkpoint blockade to promote tumor 
clearance even in unirradiated metastatic tumors, a phenomenon known as the abscopal 
effect76,77.  There have also been several anecdotal clinical cases where patients treated 
with immune checkpoint blockade received radiation at a single tumor site and 
experienced dramatic reductions in their total tumor burden78.  There are currently over 
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100 clinical trials looking at the combination of radiation and immunotherapy.  In addition 
to anti-CTLA4 and anti-PD1 there are also several other immune checkpoint antibodies in 
various stages of development.  
Lymphocyte-activation gene 3 (LAG3) is expressed on T cells and binds to class 
II MHC to downregulate the T cell response.  Mice lacking LAG3 have nearly twice the 
number of T cells as wild-type mice79.  LAG3 synergizes with PD1 to prevent autoimmunity 
in mice suggesting it could also provide a non-redundant inhibitory signal that allows 
tumors to escape PD1 therapy80.  Bristol-Meyers Squibb is currently looking at a LAG3 
blocking antibody for use in solid tumors with or without the addition of anti-PD1 
(NCT01968109).  TIM3 functions in a similar way to LAG3, it is expressed on activated 
CD8+ T cells and when it binds its ligand, galectin-9, it triggers cell death pathways in the 
T cells81.  In a murine model of colon carcinoma, almost half the intratumoral T cells were 
TIM3/PD1 double positive and adding an anti-TIM3 blocking antibody to anti-PDL1 
significantly boosted the anti-tumor response82.  A comparison of PD1 and TIM3 blocking 
antibodies is currently accruing patients (NCT02817633).  T-cell immunoreceptor with Ig 
and ITIM domains (TIGIT) is highly expressed on CD8 T cells in both humans and mice 
with cancer83,84.  Treatment with a TIGIT blocking antibody led to significant tumor 
reduction in mice83.  A trial evaluating a TIGIT blocking antibody as a single agent or in 
combination with anti-PD1 is currently recruiting participants (NCT02794571).   
It is unclear how effective these combination therapies will be in human cancers 
which display significantly more heterogeneity than mouse models and as with the 
combination of anti-CTLA4 and anti-PD1, dosing may be limited by treatment associated 
toxicities.  A CD28 agonistic antibody designed to over-activate T cells at the priming stage 
put all 6 of the healthy human volunteers in the intensive care unit for several weeks, 
demonstrating how dangerous tampering with these immune checkpoints can be85.  Given 
these risks, understanding which patients will benefit from a certain blocking antibody and 
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which will not is of critical importance.  Additionally, many patients who initially respond to 
anti-CTLA4, anti-PD1, or combination therapies eventually relapse and understanding 
these mechanisms of resistance will allow for the development of additional therapies to 
better improve response. 
Innate Resistance to Immunotherapy 
 
Resistance to immunotherapy can occur through certain intrinsic characteristics of 
the tumor cells that make them more resistant to immune mediated clearance, this is 
known as innate resistance38.  One way tumors can escape T cell mediated killing after 
anti-CTLA4 or anti-PD1 therapy is by having a low neo-antigen burden.  T cells recognize 
small fragments of peptides known as antigens86.  Each T cell expresses a unique T-cell 
receptor (TCR) on the cell surface which recognizes a unique antigen presented in a major 
histocompatibility complex (MHC) by the host cell.  CD8+ T cells recognize 8-10 amino 
acid long peptides presented by Class I MHC while CD4+ T cells recognize longer peptides 
presented by class II MHC.  Class I MHC is robustly expressed on all nucleated cells in 
the body while class II is more restricted, mainly found on certain immune subsets.  
Interaction between the TCR and the peptide/MHC complex along with co-stimulatory 
signals causes the T cell to become activated.  After activation, CD8+ T cells then divide 
and produce cytotoxic proteins such as perforin and granzyme to enable killing of cells 
expressing the peptide their TCR recognizes.   
One of the hallmarks of cancer is genomic instability and subsequent DNA 
mutations as a result of this instability87.  The mutational burden is not equal across cancer 
types, with melanoma and various subtypes of lung cancer being very highly mutated in 
patient samples, while thyroid and prostate cancer show relatively low levels of 
mutations88.  These mutations can create antigens which are not normally present in the 
host, known as neoantigens, which would be good targets for T cells activated by immune 
checkpoint blockade to recognize and eliminate 89.  Consistent with this, cancers that are 
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the most highly mutated also have the greatest proportion of patients that derive some 
benefit from treatment with anti-PD190.  A high neo-antigen signature predicted clinical 
response to anti-CTLA4 in patients with metastatic melanoma, and peptides of these 
predicted neo-antigens were able to activate T cells isolated from the patients in vitro, 
suggesting that these were the tumor specific antigens the patients’ T cells were reacting 
against91.  In 9 out of 10 patients with metastatic gastrointestinal cancer, T cells isolated 
from a tumor biopsy recognized one to three predicted neo-antigens from the patient’s 
tumor92.  Neo-antigen burden also predicted patient response to anti-CTLA4 and anti-
PDL1 in non-small cell lung cancer where the mutational load is frequently very high93.  
However, in patients with low neo-antigen burdens, there may be little for the T cells to 
react to and therefore little tumor killing after immune checkpoint blockade.  In a mouse 
model of pancreatic cancer with no strong neo-antigens, the tumor elicited very weak 
immune activation after implantation, but one synthetically engineered to express a strong 
neo-antigen was rejected upon implantation in a T cell dependent manner94.   
Since T cells rely on tumors expressing these antigens to detect and eliminate 
them, one way tumors can escape elimination is through the process of immunoediting.  
The immunoediting hypothesis is a modern version of Paul Ehrlich’s work divided into 
three distinct stages of tumor growth, elimination, equilibrium, and escape95.  In the 
elimination phase, transformed cells are spontaneously recognized and destroyed by the 
innate and adaptive immune systems.  If the cells grow quickly enough, they enter the 
equilibrium phase where tumor cells are constantly being eliminated by the immune 
system but regenerate fast enough to avoid complete tumor clearance.  Finally, in the 
escape phase the tumor escapes elimination by the immune system and grows into a 
clinically detectable tumor.  While difficult to study in humans, this process has been well 
characterized in mouse models.  Tumors from immunocompetent mice still grown when 
transplanted to other immunocompetent mice, however tumors from immune deficient 
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mice are rejected upon transplant into an immune competent mouse17.  This suggests that 
tumors developing in the presence of a competent immune system undergo changes that 
make them resistant to further immune killing while tumors from immune deficient mice do 
not.  These immunoediting changes can occur due to selective pressure from T cells or 
from components of the innate immune system such as NK cells96-98.  In patients, the 
average tumor loses between 7 and 18 neoantigens after immune checkpoint blockade, 
suggesting that immunoediting occurs in humans as well99.  Additionally, the adoptive 
transfer of antigen specific CD8+ T cells causes these antigens to be selectively lost in 
relapsed patient tumors either through reduced gene expression or loss of the mutant 
allele100.   
A related way cancers can escape elimination by the immune system is through 
the downregulation of MHC.  Even if the tumor contains several neo-antigens, without the 
ability to present these antigens to the T cells the tumor can avoid T cell mediated killing.  
Several recent clinical reports looking at metastatic melanoma patients who progressed 
on either anti-CTLA4 or anti-PD1 found an enrichment for mutations that led to 
downregulation of antigen processing and presentation suggesting this is an alternative 
way for antigen rich tumors to escape elimination101,102.  In addition to making it more 
difficult for activated T cells to recognize and eliminate the tumor through antigen loss or 
MHC downregulation, tumor cells have also co-opted the immune checkpoint signaling 
pathways to downregulate the immune response. 
As previously discussed, PD1 is expressed on activated T cells and engagement 
with its ligands PD-L1 or PD-L2 can lead to T cell anergy and deletion.  Many common 
oncogenes including EGFR, MYC, and AKT-mTOR that drive tumorigenesis can also drive 
PD-L1 expression in both human and animal cancer cell lines90,103-105.  Additionally, PDL1 
can signal into the tumor to increase glycolysis, leading to a defective T cell response 
through nutritional deprivation106.  However, some studies of the relationship between 
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these oncogenes and PD-L1 expression have failed to find this correlation in studies of 
squamous cell carcinoma as well as lung adenocarcinoma patients107,108.  Regardless of 
whether PD-L1 expression can be driven by oncogenes or through some other 
mechanism, high levels of PD-L1 on the tumor has been observed to promote resistance 
to anti-CTLA4 blockade.  In metastatic melanoma patients treated with the combination of 
radiation and anti-CTLA4, high PD-L1 levels predicted faster relapse109.  In another study 
of metastatic melanoma patients treated with anti-CTLA4 monotherapy, no correlation 
between tumor PD-L1 expression and anti-CTLA4 response was found110.  However, for 
patients in this study who progressed on anti-CTLA4 monotherapy, PD-L1 status was 
predictive of response to PD1 blockade.  It should be noted that comparing clinical trials 
can be challenging as there is no set standard of what intensity of PD-L1 staining 
constitutes a positive or high patient.  The increased PD-L1 expression in these patients 
and cell lines occurs through tumor intrinsic mechanisms and is independent of what is 
happening in the tumor microenvironment, however resistance can also arise though an 
adaptive response to signals from the tumor microenvironment, principally interferon. 
Interferon Signaling and Cancer 
 
Interferon signaling was first discovered in the context of the anti-viral response.  
Interferon was released by chick membranes upon exposure to heat inactivated virus and 
the it helped make the cells more resistant to subsequent live virus infection111.  Production 
of interferon and subsequent downstream interferon signaling is induced by components 
of the innate immune system through the toll-like receptors and other pattern recognition 
receptors, which function as molecular sensors of damage or pathogen associated 
molecular patterns such as viral DNA or RNA.  There are two main types of interferons 
(IFNs), type I which includes IFN alpha and IFN beta, and type II which has only a single 
protein IFN gamma.  There are multiple isoforms of IFN alpha, humans have 14 and mice 
have 13 all of which have a highly conserved structure and signal through a common 
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receptor, suggesting they were evolutionarily conserved for specific functions112.  
Microarray analysis of genes upregulated after treatment with IFN alpha, beta, or gamma 
shows that each IFN type upregulates genes related to a diverse array of biological 
functions113.  Some genes were induced by all three types of interferon while others were 
unique to only one.  These effects were also temporal, with over 2000 genes going up and 
back down at different times post-interferon exposure, suggesting a complex regulatory 
mechanism of interferon signaling114. 
Interferons signal into the cell by binding to their respective receptor on the cell 
surface which causes rearrangement and dimerization of the two receptor subunits 
followed by autophosphorylation of the intracellular janus kinases.  The interferon alpha 
receptor (IFNAR) is composed of two subunits IFNAR1 and IFNAR 2 which are associated 
with tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) respectively.  IFNAR binds to all 
Type I IFNs115.  After binding, JAK1 phosphorylates signal transducer and activator of 
transcription 1 (STAT1) which then forms a STAT1-STAT2-IRF9 heterotrimer.  This 
complex translocates into the nucleus and binds to IFN stimulated response elements in 
the DNA to initiate gene transcription. Like IFNAR, the interferon gamma receptor (IFNGR) 
is composed of two subunits IFNGR1 and IFNGR2 which associate with JAK1 and JAK2 
respectively.   When IFN gamma binds to IFNGR the JAKs phosphorylate STAT1, a 
STAT1/STAT1 homodimer forms which goes to the nucleus and binds gamma-activated 
sequences in the promoters of certain genes to initiate transcription112.   
The genes which are transcribed after IFN signaling are collectively known as the 
interferon stimulated genes (ISGs).  These genes and their upstream pathway 
components are often expressed at low baseline levels, but their expression is 
dramatically enhanced by IFN signaling.  This allows the cells to respond quickly after a 
pathogen or damage signal is detected.  After IFN signaling is activated, the cells enter a 
de-sensitization state that can last for several days116.  This downregulation occurs 
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through concurrent downregulation of the IFNRs by receptor mediated endocytosis as well 
as dephosphorylation of JAKs and STAT1117.  Using cyclohexamide to inhibit new protein 
synthesis after treating cells with IFN lengthens the amount of time ISGs are transcribed, 
suggesting one part of IFN signaling is creating the proteins necessary to downregulate 
the response116.  One of the most important negative regulators that is transcribed this 
way is the ubiquitin-specific peptidase 18 (USP18) which binds to the intracellular domain 
of the IFNRs and causes a conformational change which prevents further IFNs from 
binding118.  These negative regulatory pathways are critical because they allow the cells 
to recover and prevents a positive feedback loop where transcription of the ISGs drives 
continuous ISG expression which can lead to autoimmunity119. 
In addition to playing important roles in anti-viral defense and damage sensing, 
interferon signaling also plays several crucial roles in regulating the function of immune 
cells.  Type I IFN is required for the optimal cytotoxic functions of NK cells in clearing a 
murine CMV infection120.  During the anti-viral response, type I IFN also inhibits the 
proliferation of regulatory T cells and helps the proliferation of helper T cells allowing for 
improved viral clearance in mice121,122.  IFN alpha produced by dendritic cells (DCs) is 
important in blocking myeloid derived suppressor cells (MDSCs) in vitro and treating mice 
with recombinant IFN alpha blocks MDSC function in vivo123.  Interferon signaling also 
plays an important role in allowing the immune system to better attack and clear tumors.  
IFN beta improves dendritic cell cross-priming after tumor implantation which induces 
better T cell activation and improved tumor clearance124-126.  Type II IFN also plays an 
important role in anti-tumor immune activation, as IFN gamma polarizes macrophages to 
the M1 state which gives them better tumor killing capabilities127.  Besides activating the 
immune system, interferons also can function directly as anti-tumorigenic agents. 
Both type I and type II IFN can directly inhibit tumor growth.  IFN gamma slows 
proliferation and increases apoptosis in both immortalized human melanoma cell lines as 
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well as primary patient samples of head and neck cancer128,129.  These effects are dose 
dependent, as low levels of IFN gamma leads to STAT1 activation and ISG transduction 
in vitro; however higher doses induce a growth delay and even death130.  Type I IFN can 
also affect all phases of the cell cycle, blocking G1 entry, or lengthening the G2/M 
checkpoint in both immortalized and primary cells131.  Besides directly inhibiting tumor 
growth or inducing cell death, tumor-intrinsic interferon signaling can also indirectly 
improve tumor clearance.  Both types of interferon can upregulate class I MHC expression 
across a diverse array of tumor types132,133.  As previously discussed, this leads to better 
recognition of the tumor and neo-antigens by CD8+ T cells and therefore improved tumor 
clearance.   
Interferon therapy is currently being used clinically to treat some types of cancer, 
however the results have been mixed.  Recombinant interferon alpha is currently approved 
for the treatment of melanoma, Kaposi sarcoma, and several hematological malignancies.  
High risk melanoma patients who got IFN therapy had longer relapse free survival, 
however a trial in colorectal cancer did not show any benefit134,135.  Recombinant interferon 
gamma did not make it out of the clinical trial phase as some trial patients derived no 
benefit and others actually had to be stopped early because the patients receiving 
recombinant gamma were performing worse than controls136,137.  Despite well-defined 
roles for both types of interferon in controlling tumor growth and promoting immune 
mediated tumor clearance, clinical results were mixed.  This suggests that in addition to 
these anti-tumorigenic properties, interferons also may increase resistance to treatment 
or immune mediated tumor rejection. 
Interferon Mediated Adaptive Resistance to Immunotherapy 
 
Despite the immune system’s strong dependence on interferon signaling for proper 
activation and effector function in response to infections and tumors, acute interferon 
signaling can also have deleterious effects.  Mice lacking IFNAR have lower bacterial 
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loads during listeria infections and blocking type I IFN inhibited tuberculin bacterial growth 
in infected macrophages138,139.   
In tumors, IFN signaling can also promote resistance to therapy.  A subset of 
interferon stimulated genes (ISGs) known as the interferon-related DNA damage 
resistance signature (IRDS) predicted poor response to chemotherapy and loss of regional 
control after radiation in breast cancer patients140.  Expression of IFN and STAT1 mediated 
genes also predicted poor overall survival in glioblastoma multiforme141.  Only a subset of 
less than 30 ISGs were consistently expressed in these therapy resistant tumors.  One 
recent study implicated IFN signaling in resistance to anti-PD1 blockade, with ISGs slightly 
enriched in the non-responding patients142.  Interferon driven resistance is considered 
adaptive resistance as it occurs in the tumor as a response to some initial challenge such 
as radiation or immune infiltration38.  A major component of this adaptive resistance is the 
upregulation of PD-L1, the ligand for PD1, on the tumor cells.  Interferon gamma produced 
by lymphocytes induced tumor PD-L1 and promoted progression in acute myeloid 
leukemia and ovarian cancer143,144.  Interferon driven expression of PD-L1 in tumor cells 
has also been observed in several pre-clinical animal models109,145.  In addition to driving 
PD-L1 expression, IFNs can also promote the expression of other genes that promote 
resistance to immune cell mediated killing.  Another well characterized inhibitory ligand 
that is induced in the tumor after exposure to interferon is indoleamine-2,3-dioxygenase 
(IDO).  IDO is upregulated in the tumor after exposure to IFN gamma produced by CD8+ 
T cells and functions to deactivate the T cells145.  In addition to driving the expression of 
genes that downregulate the immune response, IFNs can also promote metastasis.  
Murine melanoma and breast cancer cells treated with IFN gamma in vitro displayed 
decreased growth, however when injected into mice they displayed a lung colonizing 
phenotype146,147.  In addition to these acute effects of interferon on both the immune 
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system and the tumor, chronic exposure to interferon can also have deleterious effects on 
both compartments. 
In mice infected with an incurable strain of LCMV, CD8+ T cells express an 
elevated interferon signature, and treating with a type I IFN blocking antibody after the 
infection had reached this chronic state increased immune activation, decreased 
expression of inhibitory molecules, and improved viral clearance148,149.  Blocking IFN beta 
but not IFN alpha controls the infection, demonstrating the unique roles of each IFN 
subtype150.  The temporal importance of interferon signaling can also be seen in simian 
immunodeficiency virus infected monkeys.  Type I IFN treatment initially helps control viral 
load, however if treatment is continued the infection becomes worse151.  There were also 
different effects depending on which IFN alpha was used.  Less well studied is the role of 
chronic interferon signaling on the tumor.  In vitro exposure of fibroblasts to low levels of 
IFN upregulates ISGs with no increase in pro-apoptotic or anti-proliferative ISGs114.  In 
cancer cells, chronic exposure to IFN beta drives expression of the IRDS genes and 
promotes resistance to radiation and chemotherapies similar to what has been previously 
observed in patients140,152.  Given these observations it is possible that during 
tumorigenesis or after treatment with immune checkpoint blockade, chronic interferon 
signaling in the tumor promotes these types of changes leading to treatment resistance 
and tumor relapse. 
Dissertation Objectives  
 
Interferon signaling regulates a diverse array of cell processes both in normal and 
malignant cells.  High levels of interferon signaling within tumors has been shown to 
predict poor prognosis to chemotherapy and radiation therapy, however the role of 
interferon signaling in regulating resistance to immune checkpoint blockade remains 
poorly understood.  Additionally, PD-L1 expression has been shown to correlate with 
resistance to immune checkpoint blockade, specifically combination treatments involving 
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anti-CTLA4.  PD-L1 staining has been found on both the tumor cells as well as tumor 
infiltrating lymphocytes, however, the relative importance of PD-L1 on each of these 
populations remains poorly understood.  The goal of this thesis is to address how 
interferon signaling can mediate resistance to immune checkpoint blockade through the 
following specific aims: 
1. Study the contribution of immune and tumor PD-L1 in resistance to ICB 
We hypothesize that both tumor and immune PD-L1 are capable of mediating 
suppression of the immune response after ICB.  To study this in vivo we utilized the 
CRISPR/Cas9 system to create PD-L1 knockout cell lines.  We found that in our primary 
cell lines tumor PD-L1 was the significant driver of resistance.  80% of mice with PD-L1 
KO tumors had complete tumor clearance after treatment with anti-CTLA4+RT.  In our 
resistant tumors, the response was less dramatic with only 35% of mice clearing their 
tumors.   
Utilizing flow cytometry for we identified F4/80+ macrophages as an abundant and 
PD-L1 high immune subtype.  Depleting tumor associated macrophages with an anti-
CSF1R antibody also improved response.  We also showed a differential effect of 
knocking out STAT1, a central mediator of interferon signaling, in our primary and resistant 
tumor lines.  These results suggest that additional PD-L1 independent interferon mediated 
resistance mechanisms may be present in some tumor types but not others. 
2. Study the role of chronic interferon signaling in resistance to ICB 
Given our divergent results in the STAT1 KO tumors we hypothesized that chronic 
interferon exposure in our relapse cell lines caused changes that made them more 
resistant to ICB.  To test this, we treated parental B16 cells in vitro for three weeks with 
low levels of interferon; when injected into mice the tumors were significantly more 
resistant than untreated cells.  Using ATAC-Seq we identified chromatin remodeling at 
STAT1 binding sites that had occurred because of this chronic interferon exposure.  In our 
23 
 
resistant cell lines knocking out either type I or type II IFN receptors dramatically 
resensitized the tumors to single agent ICB.   
Concomitant with this improved response we observed a marked expansion of 
deeply exhausted CD8+ T cells after ICB in the interferon receptor knockout tumors.  This 
suggests that knocking out the interferon receptors, and therefore interferon driven 
inhibitory ligands on the tumor, allows for the expansion of exhausted CD8+ T cells 
expressing the receptors for those inhibitory ligands.  This improved response was also 
recapitulated in wild-type tumors treated with a clinically available JAK inhibitor. 
Taken together, these results suggest that PD-L1 is a primary resistance 
mechanism which can be overcome with a PD1 or PD-L1 blocking antibody.  However, in 
relapsed tumors, or tumors which have already been exposed to chronic interferon, PD1 
blockade alone is insufficient to promote tumor clearance.  In these tumors, blocking 
interferon signaling through CRISPR knockout of the interferon receptors, or chemical 
inhibition of interferon signaling with a JAK inhibitor are necessary to restore sensitivity to 
ICB.  
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Chapter 2 
 
Introduction  
 
Immune checkpoint blockade (ICB) has led to unprecedented clinical responses in 
patients with a variety of metastatic cancers62,153,154.  Unfortunately, many patients still 
progress on these treatments.  Optimal clinical response will likely require combinations 
of different ICB antibodies as well as the addition of other treatments.  Several recent 
clinical reports have indicated that radiation (RT) may be one such additional treatment, 
as several patients receiving radiation and ICB had complete tumor clearance, including 
in their unirradiated tumors155-157.  We have previously reported that radiation synergizes 
with ICB to expand and reshape the T cell receptor (TCR) repertoire, both in the irradiated 
tumor as well as in the unirradiated tumor and in the periphery109.  The new TCR repertoire 
likely favors tumor-specific T cells as response was dramatically improved in mice who 
received the combination of anti-CTLA4+RT versus either treatment as a single agent.  
Radiation has also been reported to alter peptide presentation which could further assist 
in the expansion of tumor specific T cells158.  However, despite impressive initial responses 
and even complete tumor clearance and memory in a subset of the mice, many others 
were still resistant.   
When the unirradiated, “abscopal,” tumors from some of these mice were isolated 
and transplanted into naïve mice they were extremely resistant to the combination of anti-
CTLA4+RT.  RNA-sequencing on untreated bulk parental or relapsed tumors identified 
PD-L1 as one of the most upregulated genes in the resistant tumors109.  This is consistent 
with other reports that the PD1/PDL1 pathway mediates resistance to ICBs such as anti-
CTLA4 and anti-CD40159,160.  In our mouse model when a PD-L1 blocking antibody was 
combined with anti-CTLA4+RT in the parental melanoma tumors, we saw dramatically 
improved overall survival implicating PD-L1 as a mechanism for resistance to the 
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combination of anti-CTLA4+RT.  Based on these results we hypothesize that PD-L1 is a 
dominant resistance mechanism in relapse tumors and blocking it will lead to even more 
dramatic responses than in the parental tumors.   
Results 
 
As PD-L1 can be expressed by both tumor cells and immune cells50,161, to 
specifically evaluate the contribution of tumor PD-L1 to resistance we utilized the 
CRISPR/Cas9 system to ablate PD-L1 expression in the tumor cells162.  We confirmed the 
successful knockout of PD-L1 in both the parental murine melanoma cell line B16-F10 
(B16) as well as the isolated late relapse tumor that was resistant to the combination of 
anti-CTLA4+RT, called 499, using flow cytometry (Figure 1A, 1B).  As interferon gamma 
(IFNg) treatment was a known way to further increase PD-L1 in these cells145, in addition 
to untreated cells we also stimulated the cells with 100 ng/mL of IFNg for 16 hours to 
induce maximum PD-L1 expression prior to flow staining.  The PD-L1 null cell lines 
generated from B16 or 499 were termed B16 PDL1 KO and 499 PDL1 KO respectively.  
When B16 PDL1 KOs were injected into mice and treated with anti-CTLA4+RT the 
response was dramatic, with nearly 80% of the mice completely clearing their tumors 
(Figure 1C).  499 PDL1 KOs also displayed increased survival over 499; however, PDL1 
KO in this cell line did not lead to as dramatic of a response, with only one-third of mice 
completely clearing their tumors (Figure 1D).  This result was surprising given the 
enhanced PD-L1 expression in bulk 499 tumors compared to B16 by RNA-seq109.  This 
difference in survival after PD-L1 KO was also observed in a murine model of breast 
cancer.  Parental breast cancer cell line TSA, and an isolated relapse tumor after treatment 
with anti-CTLA4+RT, 237, displayed similar response kinetics after PD-L1 KO (Figure 1 
E-H).  These observations suggest that the increased PD-L1 by RNA-seq as well as the 
lower response to anti-CTLA4+RT in the relapse PDL1 KO tumor lines could be due to 
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the increased expression of PD-L1 on other cells in the tumor microenvironment, not the 
tumor cells themselves. 
To interrogate whether PD-L1 expressed in the tumor microenvironment could be 
contributing to resistance to anti-CTLA4+RT in our PDL1 KO tumors, we looked at PD-L1 
expression in untreated tumors by flow cytometry.  In both B16 and 499 tumors there was 
significant expression of PD-L1 by CD45+ tumor infiltrating lymphocytes (TILs) (Figure 2A).  
As previously reported109, there was a difference in PD-L1 staining intensity on the tumor, 
however no difference in PD-L1 positivity was observed on the TILs (Figure 2B).   Given 
the expression of PD-L1 on these immune cells, and our previous success augmenting 
response to anti-CTLA4+RT in parental B16 and 499 tumors by adding a PD-L1 blocking 
antibody109,  we decided to add a PD-L1 blocking antibody to mice bearing PDL1 KO 
tumors.  Mice injected with B16 PD-L1 KO tumors treated with the triple therapy of anti-
CTLA4+anti-PDL1+RT had no discernable benefit over mice treated with just anti-
CTLA4+RT (Figure 2C).  This lack of improved response may be due to the relative 
unimportance of PD-L1 positive TILs in mediating resistance in this model, or because 
there is such a small window for improvement that the study was underpowered to detect 
a statistically significant result.  However, 499 PDL1 KOs treated with triple therapy had a 
dramatically improved response, with close to 60% of the mice completely clearing their 
tumors, suggesting that PD-L1 expression on TILs can mediate resistance to ICB in this 
model (Figure 2D).   
Further subsetting of the TILs into specific immune lineages implicated 
macrophages as the likely driver of this PD-L1 mediated resistance.  They are both 
abundant in the tumor, comprising roughly 20% of the total TILs, and highly express PD-
L1 relative to other immune lineages in 499 tumors (Figure 3A).  Several recent clinical 
reports have found PD-L1 high macrophages in primary and metastatic patient 
samples163,164,  so we wanted to evaluate the possible role of these macrophages in 
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mediating resistance to anti-CTLA4+RT.  Macrophages have been found to play both pro- 
and anti-tumorigenic roles depending on their polarization165.  M1 polarized macrophages 
are considered to have anti-tumor functions while M2 polarized macrophages are 
generally considered to be pro-tumorigenic.  Utilizing a validated flow cytometry panel for 
characterizing macrophage polarization166, we evaluated the macrophages in untreated 
499 tumors.  We found that the tumor associated macrophages (TAMs) were 
predominantly the M2 phenotype and that M2 TAMs expressed significantly more PD-L1 
than M1 TAMs (Figure 3B, 3C).  Given these findings we hypothesized that macrophages 
were likely helping suppress the anti-tumor response after anti-CTLA4+RT.  The major 
survival cytokine for macrophages colony-stimulating factor 1 (CSF-1)167.  To deplete 
tumor-associated macrophages we utilized a blocking antibody to the receptor for CSF-1 
(CSF-1R) which was effective in depleting over 90% of the intratumoral macrophages 
(Figure 3D).  Combining anti-CSF-1R with anti-CTLA4+RT in parental 499 tumors 
significantly improved overall survival (Figure 3E).  Taken together with the anti-PDL1 
blocking antibody results, this suggests that PD-L1 on macrophages plays an 
immunosuppressive role leading to worse response after anti-CTLA4+RT.   
To test the clinical significance of these findings we utilized previously published 
results from a clinical trial of anti-CTLA4+RT in metastatic melanoma109.  We modeled 
overall survival as a function of PD-L1 surface staining and positivity on both the tumor 
cells as well as macrophages.  Both tumor and macrophage PD-L1 independently 
contribute to survival, with higher PD-L1 intensity scores on both predicting for worse 
outcome (Figure 3F).  Similar to the 499 PDL1 KO treated with anti-CTLA4+anti-
PDL1+RT, patients on the trial with low PD-L1 on both tumor and macrophages had 
improved survival but a significant fraction still had a 40-50% risk for death, implicating the 
existence of PD-L1 independent resistance mechanisms to anti-CTLA4+RT in patients as 
well as in mouse models (Figure 3G). 
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Similar to proposed models of ICB resistance168, the PD-L1 independent 
resistance mechanism observed in our mouse model of melanoma is tumor intrinsic.  JB2 
is a late relapse cell line isolated from a 499 PDL1 KO tumor treated with anti-CTLA4+anti-
PDL1+RT (Figure 4A).  These JB2 cells were still PD-L1 null, indicating resistance was 
occurring through a PD-L1 independent mechanism (Figure 4B).  When JB2s were re-
implanted into naïve mice and treated with anti-CTLA4+RT they were as resistant as 
parental 499 tumors despite expressing no PD-L1 (Figure 4C).    PD-L1 independent 
resistance was also observed in our clinical trial; several patients who progressed on the 
combination of anti-CTLA4+RT went on to receive anti-PD1 and then experienced further 
disease progression regardless of the PD-L1 status of their tumor cells and/or 
macrophages (Figure 4D).   
We have previously observed elevated levels of PD-L1 in resistant 499 tumors 
comparted to B16 both by RNA-seq and flow cytometry (Figure 2A)109.  Given that PD-L1 
has been reported to be an interferon stimulated gene (ISG)145, and high ISGs have been 
reported to correlate with resistance to multiple therapies across multiple cancer types140, 
we hypothesize differential interferon signaling could be regulating the resistance in the 
relapsed cell lines 237, 499, and JB2.  RNA-seq on untreated bulk B16 and 499 tumors 
showed comparable levels of many different types of interferon as well as their receptors 
between the two tumor types (Figure 5A).  It has also been reported that radiation can 
induce both type I and type II IFNs within the tumor169,170, suggesting that treatment could 
be causing changes in interferon expression.  In mice bearing B16 tumors, after treatment 
with anti-CTLA4+RT IFN-gamma but not Type I IFNs are detectable in the blood one week 
after treatment (Figure 5B).  Other inhibitory mechanisms including IDO and HVEM are 
also inducible by IFNg109,145, so it is possible these could be getting induced post-anti-
CTLA4+RT and mediating PD-L1 independent resistance.   
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STAT1 is an essential downstream signaling molecule and transcription factor for 
both type I and type II IFN signaling so we decided to CRISPR it out in both parental and 
ICB resistant tumors to evaluate the role of IFN induced resistance in our models (Figure 
5C and 5D).  While knocking out PD-L1 improved response in both parental and resistant 
tumors, we observed strikingly divergent phenotypes in parental and resistant tumors after 
STAT1 KO.  In both parental B16 melanoma, and TSA breast cancer tumors, STAT1 KO 
led to worse response to anti-CTLA4+RT than in wild-type tumors (Figure 5E).  
Conversely, in the resistant 499 melanoma and 237 breast cancer tumors, STAT1 KO led 
to increased response after anti-CTLA4+RT (Figure 5F).  This divergent response after 
anti-CTLA4+RT was also observed after treatment with anti-PD1 monotherapy, with 499 
STAT1 KOs doing better than wild-type while B16 STAT1 KOs had no improvement 
(Figure 5G and 5H).  Consistent with our observations in B16 and TSA tumors, loss of IFN 
signaling and/or JAK/STAT signaling has recently been reported as a resistance 
mechanism to ICB101,102.  However, it is unclear why STAT1 KO has such divergent 
functions in parental versus relapse tumors. 
Knocking out PD-L1 in addition to STAT1 in parental B16 tumors improves 
response after anti-CTLA4+RT back to wild-type tumors but provides no additional benefit 
(Figure 6A).  This suggests that in parental B16, STAT1 plays a pro-response role.  
Interestingly, despite having no better response than parental B16 tumors, STAT1/PDL1 
double KOs have a growth delay without treatment (Figure 6A).  However, resistant 499 
STAT/PDL1 2x KOs do not exhibit this same growth delay (Figure 6B), further 
emphasizing the divergent roles for STAT1 in parental and relapse tumors.  The growth 
delay in the B16 STAT1/PDL1 2x KOs is T cell dependent as using a CD8 depleting 
antibody in wild-type mice, or putting tumors into either Rag KO or Nude mice which do 
not have T cells eliminates the growth delay (Figure 6C and 6D).  One possible explanation 
for the divergent phenotypes between parental and relapse tumors is differences in 
30 
 
neoantigen burden, likely caused by immunoediting.  This is supported by the fact that 
499s have lost several predicted high-affinity neoantigens when compared to parental 
B16s (Figure 6E).  The 499 PDL1 KO late relapse cell line JB2 further lost several neo-
antigens compared to the original 499 PDL1 KO cell line further supporting this idea 
(Figure 6E).  Since STAT1 signaling is necessary for antigen presentation171, knockout out 
STAT1 in the neo-antigen high parental B16s has a deleterious effect on the T cells’ ability 
to recognize and eliminate the tumor.   
Discussion 
 
Understanding how tumors become resistant to ICB or combination therapies is 
critical to identifying biomarkers of resistance as well as developing novel treatments to 
combat resistance.  Increased expression of PD-L1 by the tumor cells or other cell types 
such as tumor infiltrating lymphocytes can mediate resistance to therapies that do not 
block PD1/PDL1.  This PD-L1 mediated resistance can be innate to the tumor as a result 
of oncogene driven tumorigenesis, or adaptively upregulated by cytokines such as 
interferon during an immune response145,168.  Previously, we have reported that adding 
anti-PDL1 to anti-CTLA4+RT leads to dramatic improvements  in overall survival109.  Here 
we show that in our primary mouse models of metastatic melanoma and breast cancer 
that tumor PD-L1 plays the dominant role in mediating resistance to anti-CTLA4+RT.  
Adding anti-PDL1 does not appreciably improve response, suggesting that the observed 
benefits of adding anti-PDL1 primarily come through blocking tumor PD-L1 in this model.  
In our late relapse models, however, ablating PD-L1 through CRISPR/Cas9 improves 
response but not nearly as dramatically as in the parental cell lines implicating additional 
acquired mechanisms such as differences in PD-L1 in the tumor microenvironment or 
additional tumor-intrinsic mechanisms.  Relapse tumors had high levels of 
immunosuppressive macrophages which are PD-L1 high and contribute to resistance.  
The role of macrophages in resistance has also been observed in clinical samples 
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although the polarization of the macrophages was not evaluated.  Given the conflicting 
clinical reports about the role of macrophages in tumor progression, further study is 
necessary to evaluate the potential value of utilizing a macrophage depleting antibody as 
an adjuvant therapy.  In addition to PD-L1 on either the tumor or TILs there are likely PD-
L1 independent resistance mechanisms as evidenced by our clinical trial data of patients 
who received anti-CTLA4+RT then anti-PD1 and still had progression regardless of PD-
L1 status. 
One potential mechanism for resistance in these patients and in our relapsed 
mouse tumors is neo-antigen loss through immunoediting95.  Both 499 and JB2 lost two 
high affinity and several lower affinity predicted Class I neo-antigens compared to their 
respective parental cell lines.  This observation helps explain the differential response in 
499s compared to B16 when PD-L1 is knocked out, as well as why JB2 are resistant to 
anti-CTLA4+RT even though they do not express PD-L1.  However, further work is 
required to directly implicate these lost neo-antigens in promoting resistance, and closer 
tracking of human patients during clinical trials is necessary to monitor the neo-antigen 
load and how it relates to resistance in patients.  Additionally, it remains unclear whether 
Class I or class II neo-antigens are more important in mediating response172, and further 
work is necessary to identify and study any class II neo-antigens that may also be involved 
in mediating response in the parental cell lines which are lost in our relapse cell lines.  
While neo-antigen loss is observed in both our patient and mouse models and correlates 
with relapse and resistance it is experimentally challenging to intervene to correct this.  
Combatting antigen loss would require activating the immune system against weaker neo-
antigens and self-antigens possibly through relaxing tolerance.   
A promising avenue to improve response in relapse tumors is through inhibiting 
STAT1.  Knocking out STAT1 in our relapse 499 melanoma and 237 breast cancer models 
significantly re-sensitized tumors to anti-CTLA4+RT.  This improved response is likely 
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through a combination of reduced expression of T cell inhibitory ligands such as PD-L1 as 
well as other unidentified mechanisms.  STAT1 is a central regulator of both type I and 
type II IFNs but also has other IFN independent roles173.  Understanding whether STAT1 
mediated resistance is through type I or type II IFN signaling, IFN independent 
mechanisms, or some combination of these, as well as what resistance mechanisms these 
pathways regulate will be critical for identifying approaches to re-sensitize resistant tumors 
to ICB.  Additionally, STAT1 KO had divergent effects in parental versus relapse tumors 
with parental STAT1 KOs responding worse than wild-type to anti-CTLA4+RT while 
relapsed KO tumors responded better.  Understanding why this divergent phenotype 
occurs, how relapsed parental tumors become dependent on STAT1 to maintain 
resistance, and biomarkers of this process are all necessary to identify which patients 
would benefit from therapies to block STAT1 signaling to improve response to ICB or the 
combination of ICB and other therapies such as radiation.   
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Figure 1:  Tumor PD-L1 mediates resistance to the combination of anti-CTLA4 and 
radiotherapy 
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Figure 1: A and B) PDL1 expression on parental B16 melanoma (A) or relapse 499 (B) 
with or without CRISPR knockout of PDL1.  C) Survival after RT+anti-CTLA4 for mice with 
B16 tumors or tumors with PDL1 knocked out.  D) Survival after RT+anti-CTLA4 for mice 
with 499 tumors or tumors with PDL1 knocked out.  E and F) PDL1 expression on parental 
TSA breast cancer (E) or relapse 237 (F) with without CRISPR knockout of PDL1.  G) 
Survival after RT+anti-CTLA4 for mice with TSA tumors or tumors with PDL1 knocked out.  
H) Survival after RT+anti-CTLA4 for mice with 237 tumors or tumors with PDL1 knocked 
out.   
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Figure 2: Immune cells expressing PD-L1 mediate resistance to anti-CTLA4 and 
radiotherapy in relapse but not parental tumor lines 
 
 
 
Figure 2: A) Representative contour plot of in vivo PDL1 expression on melanoma cells 
(red) and CD45+ immune cells (blue) from B16 or Res 499 tumors.  B) Median 
fluorescence intensity of PDL1 on immune cells from B16 or 499 tumors.  C) Survival after 
either RT+anti-CTLA4 or RT+anti-CTLA4+anti-PDL1 in mice with B16 PDL1 knockout 
tumors.  D) Survival after either RT+anti-CTLA4 or RT+anti-CTLA4+anti-PDL1 in mice 
with Res 499 PDL1 knockout tumors.     
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Figure 3: Macrophages expressing PD-L1 portend relapse after treatment in both 
murine models and patient samples  
 
 
 
Figure 3: A) Histogram plot of relative PDL1 expression on the indicated immune cell 
populations in Res 499 tumors.  B) Percent of F4/80+ macrophages polarized as M1 or 
M2 in a Res 499 tumor.  C) MFI of PDL1 on the macrophages from B. D) Percentage of 
CD45+ immune cells that are F4/80+ in Res 499 tumors 10 days after starting anti-CSF1R.  
E) Survival of mice treated with RT+anti-CTLA4 with or without anti-CSF1R.  F) Overall 
survival of metastatic melanoma patients treated on a clinical trial of RT+ anti-CTLA4 was 
modeled by random survival forest using the percentage of PDL1+ melanoma cells or 
macrophages or the PDL1 IHC staining intensity score (0-3) on melanoma cells, 
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macrophages, or both.  The prediction error rate for the model is 38.7+/- 0.01% with n=13.  
Shown are the variable importance scores with Monte Carlo standard deviations, as a 
measure of how strongly the variable contributes to prediction accuracy.  G) Predicted 
survival of metastatic melanoma patients treated with RT+anti-CTLA4 modeled by random 
forest using the combined IHC PDL1 intensity score on melanoma cells and macrophages.  
Estimates are based on out-of-bag samples. 
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Figure 4: PD-L1 independent resistance to immune checkpoint blockade occurs in 
both mice and patients 
 
 
Figure 4: A) Schematic of the development of the JB2 cell line, which is from a Res 499 
PDL1KO tumor, relapsed 2 months after therapy.  B) In vitro flow cytometry for PDL1 
expression on parental 499 or JB2 confirming JB2 were still PDL1KO.  C) Tumor growth is 
mice treated with or without RT+anti-CTLA4 (n=5).  D)  Overall survival after starting anti-
PD1 for patients initially treated with RT+anti-CTLA4 on a clinical trial.  Progression, time 
of progression, and death after anti-PD1 are indicated.   
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Figure 5: Differential effects of STAT1 knockout in parental and relapse tumors 
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Figure 5: A) Relative expression of IFN and IFN receptor genes from whole tumor lysates.  
Mean (gray line) and first and third quartiles (dashed lines) of all genes on the microarrays 
are indicated.  Error bars are SDs.  B) Relative expression of IFN and IFN receptor genes 
from whole tumor lysates.  Mean (gray line) and first and third quartiles (dashed lines) of 
all genes on the microarrays are indicated.  Error bars are SDs. IFNg levels in the blood 
of mice bearing B16 tumors after RT+anti-CTLA4 (n=7). *p<0.05.  C) Expression of PDL1 
(an ISG responsive to type I and type II IFN signaling) on B16 and B16 cells with STAT1 
knockout (left) or Res 499 and 499 STAT1 knockout (right).  D) Expression of PDL1 (an 
ISG responsive to type I and type II IFN signaling) on TSA and TSA cells with STAT1 
knockout (left) or Res 237 and 237 STAT1 knockout (right).  E) Survival after RT+anti-
CTLA4 for mice with B16 or B16 STAT1KO tumors (left) or TSA and TSA STAT1KO tumors 
(right).  F) Survival after RT+anti-CTLA4 for mice with Res 499 or 499 STAT1KO tumors 
(left) or Res 237 and 237 STAT1KO tumors (right).  G) Survival after treatment with anti-
PD1 monotherapy in mice with B16 or B16 STAT1KO tumors.  H) Survival after treatment 
with anti-PD1 monotherapy in mice with Res 499 or 499 STAT1KO tumors.   
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Figure 6: Neoantigen loss correlates with resistance to treatment 
 
 
 
Figure 6: A) Survival after treatment with RT+anti-CTLA4 in mice with B16 or B16 
STAT1/PDL1KO tumors.  B) Survival of untreated mice injected with Res 499 or 499 
STAT1/PDL1Ko tumors.  C) Survival of mice after injection with B16 STAT1/PDL1KO tumors 
with or without anti-CD8a antibody treatment.  D) Survival of wild-type (C57bl/6), athymic 
(nude), or Rag2 (Rag KO) mice after injection with B16 (left) or B16 STAT1/PDL1KO (right) 
tumors.  E) Predicted MHC-I affinity of non-synonymous somatic mutations that have 
undergone loss or near-loss of heterozygosity (LOH) in Res 499 compared to parental 
B16. For each mutation, all 8, 9, and 10-mer peptides containing the amino acid mutation 
were determined and the H-2Kb and H-2Db affinity calculated using IEDB and the artificial 
neural network method. Shown is the reciprocal of the affinity for all peptides. Those 
exceeding 500 nM (blue dashed line) and 20 nM (red dashed line) are labeled. Peptides 
from genes showing no evidence of expression by RNA-seq were omitted.  
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Chapter 3 
 
Introduction 
Immune checkpoint blockade (ICB) is rapidly becoming an effective therapeutic 
option for several cancer types168. Despite this success, resistance and relapse are 
common. One important mechanism of resistance is the upregulation of PDL1168,174, a 
ligand for the T cell inhibitory receptor PD1. T cell inhibitory receptors (TCIRs), or immune 
checkpoint receptors, such as PD1, promote tolerance to self-antigens and limit immune-
mediated pathology that can result from persistent antigen and chronic inflammation58. 
PD1 serves this negative regulatory function by promoting T cell exhaustion. Exhausted T 
cells (TEX) have reduced proliferative and functional capacity that includes diminished 
cytokine and cytolytic activity. This dysfunctional state can be partially reversed, or 
reinvigorated, to improve effector function. Hence, the clinical activity of PD1/PDL1 
blockade in cancer may be related to the reinvigoration of TEX that develops as a result of 
a pre-existing immune response or to preventing the development of TEX after therapy is 
initiated. 
An additional hallmark of TEX is the expression of multiple inhibitory receptors, such 
as CTLA4, TIM3, LAG3, TIGIT, and others58,175. The co-expression of multiple TCIRs on 
TEX suggests that these additional inhibitory pathways may drive PD1/PDL1-independent 
resistance mechanisms that can be targeted to improve responses. Across several cancer 
types, up to 50% of patients with PDL1+ tumors are either resistant or relapse after 
PD1/PDL1 blockade71,176,177, consistent with the need to antagonize parallel PDL1-
independent resistance mechanisms. However, how to rationally combine ICB agents with 
each other or other therapies is not obvious. In particular, the TEX population appears 
heterogeneous in TCIR expression, exhaustion-related markers, and reinvigoration 
potential178-181. For example, in chronic viral infections, TEX expressing high levels of 
multiple TCIRs are considered less susceptible to reinvigoration by PD1/PDL1 blockade. 
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Thus, approaches to effectively prevent the development of or reinvigorate a broader and 
more recalcitrant subset of TEX may have therapeutic importance for immunotherapy.  
The balance between immune-mediated tumor elimination and escape is 
influenced by many factors. Interferons (IFNs) are typically considered important in the 
generation of an anti-tumor immune response. Type I IFN (IFN-I) promotes dendritic cell 
function and CD8 T cell cross-priming, whereas interferon-gamma (IFNG), a type II IFN, 
influences both host and tumor cells to favor rejection of highly immunogenic tumors182. 
Both IFNs appear to be particularly critical for early T cell priming and activation events 
with less effect on tumor response when either is antagonized at later times183. In contrast, 
under conditions of prolonged IFN signaling and persistent antigen exposure, 
accumulating evidence indicates that IFNs can have immunosuppressive roles184. For 
example, in cancer the upregulation of PDL1 by IFNG is an “adaptive resistance” 
mechanism. Here, tumor cells respond to IFNG as part of a negative feedback event to 
inhibit the immune response145. Countering adaptive resistance appears to be a major 
therapeutic effect of PD1/PDL1 blockade. In total, these observations suggest that 
opposing immunomodulatory functions of IFNs may influence the balance between 
immune-mediated elimination and immune escape. 
Recently, we examined the molecular and immune determinants of response to 
the combination of anti-CTLA4 and radiation (RT) for metastatic melanoma109. Although 
the combination regimen can result in durable responses with RT contributing to T cell 
repertoire diversification and ICB driving oligo-clonal T cell expansion, a majority of mice 
and patients treated with RT + anti-CTLA4 were either resistant or relapsed. The 
upregulation of PDL1 in the tumor was determined to be an important resistance 
mechanism to RT + anti-CTLA4 and was associated with persistent T cell exhaustion or 
poor reinvigoration as measured in the post-treatment blood of mice and patients. 
However, although the addition of anti-PD1/PDL1 to RT + anti-CTLA4 improved 
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responses in mice, resistance and/or relapse still occurred, indicating the existence of 
additional immunosuppressive pathways.  
Results 
 
Prolonged Tumor IFN Signaling Drives PDL1-independent Resistance to ICB 
IFNG drives PDL1 expression, which may be regulated by either type I or II IFNs. 
Therefore, we sought to investigate whether IFNs could orchestrate resistance beyond the 
upregulation of PDL1. Both Res 499 and JB2 were derived from tumors that initially 
responded to RT + ICB but subsequently relapsed several weeks after initiation of therapy. 
Type I and II IFN transcripts are present in both B16 and Res 499 whole tumors (Figure 
5B) and can increase significantly after therapy, in particular IFNG (Figure 5A). To 
potentially mimic IFN conditions in the tumor microenvironment post-therapy, we treated 
parental B16 cells with various doses of either IFNG or type I IFN (IFN-I) for two weeks in 
culture, followed by removal of IFN and continuous culture for another week. Treating B16 
cells with prolonged IFNG (B16γ) was sufficient to confer resistance to RT + anti-CTLA4 
to levels approaching Res 499 (Figure 7A-B). In contrast, prolonged IFN-I signaling did 
not confer resistance (Figure 8A) and signaling through type III IFNs was not detected 
(Figure 8B). These results demonstrate that exposure to persistent IFNG is sufficient to 
render sensitive melanoma resistant to RT + anti-CTLA4. 
Prolonged tumor growth accompanied by an ineffective T cell response would be 
expected to result in persistent IFN exposure in vivo. Therefore, to examine whether 
acquisition of resistance in vivo can occur after prolonged tumor growth and IFN exposure, 
we used three different treatment schedules that first allowed tumors to grow to 
substantially larger sizes prior to therapy (Figure 7C). For the treatment, anti-PDL1 instead 
of RT was combined with anti-CTLA4 to eliminate rapid cytoreduction from RT and to 
examine for PDL1-independent resistance. As expected, mice with B16 tumors responded 
to a standard dosing schedule at day 5 but failed to respond when therapy was delayed 
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until day 10 (Figure 7D). In contrast, mice bearing B16 tumors with knockout of the IFNG 
receptor (IFNGRKO) (Figure 8C) maintained their ability to respond despite the delay. 
Importantly, IFNGRKO had no effect on B16 tumors when therapy was not delayed (Figure 
7D, D5 schedule), supporting the notion that signaling through the tumor IFNG receptor 
was not influencing primary resistance but rather driving PDL1-independent adaptive 
resistance. 
Even though prolonged IFN-I signaling in vitro did not appear sufficient to confer 
resistance, we investigated whether the IFN-I receptor (IFNAR) might influence B16 tumor 
response when ablated with IFNGR. In the absence of therapy, double IFNGR and IFNAR 
knockout (IFNA/GRKO) tumors (Figure 8D) displayed similar tumor growth as control 
tumors (Figure 8E) and similar to IFNGRKO tumors (Figure 8F). However, when treatment 
was delayed until day 13 (but not earlier), IFNA/GRKO appeared more effective than 
IFNGRKO at sustaining responsiveness to therapy (Figure 7E). This effect of IFNAR was 
observed only after prolonged tumor growth and therapy delay prompting us to examine 
the role of each IFN receptor in maintaining resistance.  
Type I and II IFN Signaling in Tumor Cells Maintains PDL1-independent Resistance 
To distinguish a role for type I and/or II tumor IFN signaling in maintaining as 
opposed to initiating resistance, we utilized Res 499 tumors with IFNGRKO or IFNAR 
knockout (IFNARKO) (Figure 8G-H). This revealed that disrupting either IFN receptor did 
not alter Res 499 tumor growth in the absence of treatment (Figure 7F) but restored 
response of these resistant tumors to RT + anti-CTLA4 to levels similar to parental B16 
tumors (Figure 7G and 7B). Examination of in vivo transcriptomic changes demonstrated 
that each receptor partially diminished expression of top upregulated genes representing 
transcriptomic features acquired by Res 499 tumors as a consequence of relapsing after 
RT + anti-CTLA4 (Figure 7H). IFNA/GRKO (Figure 8I) led to the largest decrease in genes 
associated with resistance and had the largest effect on multiple biological processes 
46 
 
related to IFN signaling as well as other pathways (Figure 10A). Given the more 
comprehensive effect of IFNA/GRKO, we knocked out both IFN receptors in JB2 cells to 
directly establish their role in maintaining PDL1-independent resistance (Figure 8J). 
Indeed, despite JB2 cells lacking PDL1 and having acquired resistance through PDL1-
independent means, IFNA/GRKO restored response of JB2 tumors to RT + anti-CTLA4 
(Figure 7I). Thus, these results indicate that type I and II IFN signaling contributes to 
maintaining a PDL1-independent resistance state. 
Prolonged IFN Drives STAT1-Related Epigenomic and Transcriptomic Features of 
Resistant Tumors 
The effect of prolonged IFNG signaling in vitro and in vivo on PDL1-independent 
resistance suggests possible epigenetic influence. Indeed, persistent IFNG stimulation 
resulted in elevated levels of constitutive STAT1 as observed in B16γ cells even after 
continuous culture in the absence of exogenous IFNG (Figure 9A). To investigate if 
elevated STAT1 might be associated with how the epigenome responds to in vivo signals 
in the tumor microenvironment, we performed ATAC-seq on sorted melanoma cells to 
assess differences in open chromatin regions (OCRs). This revealed that prior chronic 
IFNG exposure alters the in vivo epigenome of B16 to partially resemble that of Res 499 
(Figure 9B). Analysis of differential OCRs in B16γ and Res 499 relative to B16 
demonstrated that a significant fraction (45.9%) of differential OCRs acquired by B16γ 
overlapped with those acquired by Res 499 (Figure 9C). A de novo motif search showed 
that many motifs within the differential OCRs found in B16γ and Res 499 significantly 
matched to STAT1 sites (Figure 10B) and many were shared between B16γ and Res 499 
(Figure 9C, p=5.3 x 10–47 for overlap by hypergeometric test). ATAC-seq revealed DNA 
footprinting centered at discovered STAT1 motifs, and these footprints increased in Res 
499 and B16γ relative to B16, consistent with increased STAT1 occupancy within these 
OCRs (Figure 9D). This increase in inferred STAT1 occupancy and STAT1 levels in B16γ 
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was correlated with the in vivo acquisition of transcriptomic features associated with 
relapse from RT + anti-CTLA4 (Figure 10C, left). Indeed, these transcriptomic features 
showed a high degree of STAT1-dependency as demonstrated by STAT1KO in Res 499 
tumors (Figure 10C, right). STAT1KO in Res 499 also inhibited resistance to RT + anti-
CTLA4 (Figure 9E-F), and STAT1KO together with PDL1KO (Figure 10D) led to better tumor 
response compared to either knockout alone, consistent with STAT1 regulating PDL1-
independent resistance. Thus, prolonged IFNG alters the melanoma epigenome in vivo to 
partially resemble that of resistant tumors. STAT1 occupancy may underlie a significant 
proportion of these changes to influence transcriptomic features of resistant tumors and 
to regulate PDL1-independent resistance pathways.  
A Multigenic Resistance Program of TCIR Ligands and ISGs 
Genome-wide effects of persistent IFN signaling and acquisition of PDL1-
independent resistance appeared to converge onto enhanced STAT1 expression and/or 
activity. Thus, we reasoned that genes associated with STAT1 could provide insight into 
effectors involved in PDL1-independent resistance. Due to the large number of genes 
differentially expressed in Res 499 compared to B16, we integrated transcriptomic data 
from mice and patients to examine only genes that included: 1) annotated type I and II 
IFNs, 2) ISGs that we previously described to be robustly expressed across human 
cancers140, and 3) common T cell inhibitory receptors (TCIRs), their ligands, and 
immunosuppressive effectors such as IDO1. Analysis of unsorted Res 499 and B16 
tumors revealed that in resistant tumors Stat1 preferentially correlated with genes 
encoding multiple TCIR ligands that included TNFRSF14 (HVEM), LGALS9 (Galectin-9), 
and MHC class II (MHCII) – ligands for CD160 and BTLA, HVARC2 (TIM3), and LAG3, 
respectively (Figure 9G). A similar pattern was observed with the ISGs Ifit1 and Mx1. 
Using expression data from TCGA, we sought to corroborate the significance of 
the TCIR ligands and ISGs that preferentially associate with STAT1 in resistant mouse 
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tumors. Because many of the examined genes may simply correlate with the presence of 
a T cell infiltrate, we also added CD8A, GZMA, and PRF1, which can act as a surrogate 
for T cell infiltration and cytolytic activity185. Despite a high degree of correlation among 
most of the examined genes (Figure 9H), network analysis reveals that STAT1 is the only 
gene that connects the IFNG/CD8 T cell infiltrate genes, ISGs, and a cluster of TCIR and 
TCIR ligands through PDL1 (Figure 9I). To mimic the effect of elevated PDL1 found in Res 
499 compared to B16, we examined how correlations between STAT1 and other genes in 
the network change when PDL1 gene expression is high versus when it is low (Figure 9J). 
Indeed, when PDL1 is high, STAT1 more strongly and significantly correlates with 
TNFRSF14, LGALS9, MHCII, CD86, and the ISGs MX1 and IFIT1 compared to when 
CD8A levels are high, suggesting that these associations are not simply due to higher T 
cell infiltration. Thus, in both Res 499 tumors and human melanoma tumors with high 
PDL1 expression, an overlapping set of TCIR ligands and ISGs preferentially associate 
with STAT1. We denote this set of multiple TCIR ligands (PDL1, TNFRSF14, LGALS9, 
MHCII, CD86) and cancer-associated ISGs (IFIT1 and MX1) as IDILS, or Interferon-Driven 
Inhibitory Ligands and ISGs. Transcriptomic analysis of sorted tumor cells revealed that 
IDILS increases in B16γ compared to B16 and decrease as a consequence of STAT1KO 
(Figure 9K). Treatment of Res 499 cells in vitro with IFNG or IFN-Is confirmed that IFNs 
directly regulate the TCIR ligands that comprise IDILS (Figure 11A). Thus, IDILS is IFN 
and STAT1-dependent and increases as a result of prolonged IFNG signaling. 
Inhibiting Tumor IFN Signaling Antagonizes Multiple TCIR Ligands and Resistance 
Examining in vivo expression of IDILS TCIR ligands confirmed elevated expression 
in Res 499 compared to B16 (Figure 11B, top two rows). B16γ showed increased 
expression for most, but not all, of these ligands, and this expression was generally 
intermediate between B16 and Res 499. Interestingly, although most TCIR ligands are 
influenced by both type I and II IFNs, some ligands like LGALS9 are preferentially affected 
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by IFN-I, while others such as MHCII are predominantly influenced by IFNG (Figure 11A). 
Indeed, distinct effects by type I versus type II IFNs on TCIR ligands and other IDILS 
genes are observed in vivo when each receptor is disrupted, and the most severe effects 
on IDILS occurs with IFNA/GRKO (Figure 11C). The effect of IFNA/GRKO and the STAT1-
dependency of TCIR ligands was also confirmed by flow cytometry of in vivo tumors 
(Figure 11B, bottom two rows). Thus, inhibiting both IFN receptors in tumor cells effectively 
collapses IDILS and its multiple TCIR ligands. 
To assess whether IDILS TCIR ligands can contribute to PDL1-independent 
immune suppression, we used a combination of genetic and blocking antibody 
approaches. Given the near-absent baseline expression of TNFRSF14 and reports that it 
can interact with multiple TCIRs that include CD160 and BTLA186, we utilized CRISPR to 
ablate TNFRSF14 in Res 499 PDL1KO tumors (Figure 12A). The additional blockade of 
the TNFRSF14 pathway improved response to RT + dual blockade of PDL1 and CTLA4 
(Figure 11D). To interrogate LGALS9 and MHCII, a blocking antibody to TIM3 and LAG3 
were used, respectively. For these experiments, RT was omitted due to unexpected high 
toxicity when RT was combined with triple ICB (data not shown). Nonetheless, blocking 
either the LGALS9/TIM3 or MHCII/LAG3 pathways improved response to dual blockade 
of CTLA4 and PDL1, while quadruple blockade had the best effect (Figure 11E-F). 
Blocking TIM3 and LAG3 also improved ICB efficacy in the Res 237 resistant breast 
cancer model (Figure 11G). Similar to Res 499, Res 237 tumor cells originated from a 
breast tumor that initially responded to RT + anti-CTLA4 but relapsed weeks later. Thus, 
IDILS TCIR ligands can contribute to PDL1-independent resistance. 
Although initial response to ICB is improved by blocking multiple IDILS TCIR 
ligands, most mice relapse (Figure 11F-G); however, we reasoned that IFNA/GRKO would 
be more effective, due to disruption not only of multiple TCIR ligands but other IDILS and 
IFN-associated pathways as well (Figure 7H, Figure 10A). Indeed, IFNA/GRKO markedly 
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improved response and survival to anti-CTLA4 + anti-PDL1 compared to addition of TIM3 
and/or LAG3 blockade (Figure 11H). Thus, interfering with multiple TCIR ligands and 
potentially other suppressive mechanisms associated with IDILS effectively improves ICB 
response and survival. 
Inhibiting IFN-Driven Resistance Expands Distinct Populations of Exhausted T Cells 
after ICB 
Exhausted T cells are a heterogeneous population that differs in their capacity for 
reinvigoration after ICB. Part of this heterogeneity is due to increased severity of 
exhaustion with increasing co-expression of multiple TCIRs. We reasoned that interfering 
with multiple TCIR ligands as part of blocking IDILS could enhance expansion of the T cell 
repertoire particularly by affecting severely exhausted T cells co-expressing multiple 
TCIRs. To investigate this, we first developed an approach to identify populations of T 
cells expressing distinct TCIR co-expression patterns (Figure 12B). Nine robust T cell 
clusters were identified (Figure 13A-B, Figure 14A). T cells in four clusters express either 
high or intermediate levels of PD1 (Cl.1, Cl.5.2, Cl.5.3, Cl.5.5). Among these, clusters Cl.1 
and Cl.5.5 exhibit co-expression of multiple TCIRs but lack high expression of any 
individual TCIR (PD1intTCIRlow cluster). In contrast, Cl.5.2 and Cl.5.3 are PD1highTCIRhigh 
clusters showing highly elevated expression of multiple TCIRs (Figure 13B), a cardinal 
feature of severely exhausted T cells175. 
Although all T cell clusters could be identified in the tumor, tumor-reactive CD8 
TILs, as measured by a tetramer to the known melanoma antigen TRP2187, predominantly 
belonged to the PD1highTCIRhigh Cl.5.2 and Cl.5.3 clusters (Figure 14B). The proportion of 
T cells in these PD1highTCIRhigh clusters either increased or remained the same after 
treating mice with Res 499 tumors with anti-CTLA4 + anti-PDL1. Furthermore, the 
proportion of Ki67+GzmB+ TILs in either the total CD8 TIL population (Figure 13C) or in 
TILs from individual clusters failed to increase (Figure 13D-E). In contrast, IFNA/GRKO or 
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STAT1KO altered the frequency of TRP2+ CD8 TILs in response to dual ICB, resulting in 
an increase in the proportion of PD1highTCIRhigh Cl.5.2 T cells (Figure 14B-C). This was 
accompanied by an ICB-mediated increase in the proportion of Ki67+GzmB+ TILs (Figure 
13C) that preferentially affected the Cl.5.2 cluster (Figure 13D-F). Thus, blocking tumor 
IFN signaling along with ICB leads to a preferential accumulation of PD1highTCIRhigh Cl.5.2 
TILs with markers of improved function. 
To better assess population expansion dynamics, we performed serial analysis of 
peripheral blood on mice before and after anti-CTLA4 + anti-PDL1. After dual ICB (given 
on day 13), mice with Res 499 IFNA/GRKO tumors demonstrated a large expansion in 
PD1+ peripheral T cells compared to mice with wild type Res 499 tumors (Figure 13G). 
Furthermore, IFNA/GRKO led to a larger fraction of PD1+ T cells that were Ki67/GzmB 
positive despite concomitantly expressing Eomes, a transcription factor typically 
expressed by severely exhausted T cells with limited proliferative potential. This increase 
was apparently driven by a larger proportion of PD1+ T cells belonging to the 
PD1highTCIRhigh Cl.5.2 and Cl.5.3 clusters (Figure 13H) and by the preferential increase in 
the fraction of Eomes+ Ki67+GzmB+ T cells in both of these populations (Figure 13I). In 
contrast, the PD1low/int and/or TCIRlow populations Cl.1, Cl.5.1, and Cl.5.5 failed to show a 
similar increase. For the PD1highTCIRhigh Cl.5.2 population, the expansion of Eomes+ 
Ki67+GzmB+ T cells resulting from IFNA/GRKO was associated with an increase in both the 
proportion of Eomes+ versus Eomes– T cells and in the fraction of Eomes+ T cells that 
were Ki67+GzmB+ (Figure 13J-K). For the PD1highTCIRhigh Cl.5.3 group, the vast majority 
of T cells already expressed Eomes irrespective of IFN receptor status. In total, these 
observations suggest that crippling multiple TCIR ligands and IDILS results in 
accumulation of distinct populations of PD1highTCIRhighEomes+ TEX that otherwise would 
be recalcitrant to reactivation. 
Targeting IFN-Driven Resistance Restores Response to ICB Monotherapy 
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Tumor IFN signaling drives expression of IDILS genes, contributes to PDL1-
independent resistance to RT + anti-CTLA4, and can be ablated to preferentially expand 
otherwise severely exhausted T cells and improve response to combination ICB. We 
reasoned that if inhibiting IDILS is functionally equivalent to blocking multiple TCIR 
pathways and other suppressive genes en bloc, such an effect might even restore 
sensitivity to ICB monotherapy. Indeed, although triple or quadruple ICB was required to 
significantly improve response of Res 499 tumors (Figure 11E-F), IFNGRKO and/or 
IFNARKO allowed for response to anti-PD1 monotherapy and to anti-CTLA4 monotherapy 
(Figure 15A) with the largest effect typically observed with IFNA/GRKO. In fact, when both 
type I and II IFN receptors were eliminated from Res 499 tumors, complete responses and 
long-term survival were observed after anti-CTLA4 monotherapy (Figure 15B). 
Remarkably, with Res 237 breast cancer tumors, which also show elevated levels of 
genes involved in IFN-driven resistance (Figure 16A), IFNA/GRKO led to 100% complete 
response and survival after anti-CTLA4 alone (Figure 15C). Improved response to ICB 
monotherapy after inhibiting tumor IFN signaling was CD8 T cell dependent (Figure 16B-
C). Accordingly, MHC class I surface expression was maintained in vivo despite blocking 
tumor IFN signaling, albeit at expectedly lower levels (Figure 16D-E). This constitutive 
MHC-I is consistent with baseline expression of MHC-I and antigen processing machinery 
observed across melanoma and breast cancer cell lines largely in the absence of IFNs 
(Figure 16F).  
Similar to genetic ablation, administration of a JAK1/JAK2 inhibitor (JAKi) 
ruxolitinib decreases multiple TCIR ligands on tumor cells (Figure 15D, Figure 16G). At 
the dose used, effects on immune cells appeared less pronounced, although downward 
trends in expression were evident. A delayed administration of JAKi after start of ICB 
(Figure 15E, D8 schedule) resulted in improved response of both Res 499 melanoma and 
Res 237 breast cancer tumors (Figure 15F-G). Starting JAKi at the same time as anti-
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CTLA4 did not result in improved response (Figure 15E-F, D5 schedule), consistent with 
the requirement for early IFN signaling for immune cell function183. In total, these results 
demonstrate that inhibiting IFN signaling genetically or pharmacologically can restore 
response to ICB monotherapy even with tumors that are highly resistant to extensive ICB 
combination therapy. 
High Expression of ISGs Can Associate with Clinical Progression After Anti-PD1 
The IDILS resistance program is comprised of two ISGs, IFIT1 and MX1. Since 
these ISGs are co-expressed with the TCIR ligands and also regulated by tumor IFN 
signaling, we examined whether their expression could be associated with lack of clinical 
response to ICB. To test this, we used the average expression of IFIT1 and MX1 and 
computationally modeled clinical response to anti-PD1 using a recently published cohort 
of melanoma patients142. To guard against bias, out-of-bag (OOB) samples, or samples 
not used in constructing the model, provided estimates of model error rate and variable 
importance scores. Given the known association between neo-antigen burden and anti-
PD1 response188, we included the number of non-synonymous somatic mutations, or 
single-nucleotide variants (nsSNVs), in the model. The OOB error rate for overall accuracy 
and association with response or progression were all approximately 39%, which likely is 
influenced by the small sample size (Figure 17A). Both nsSNVs and IFIT1/MX1 
contributed to prediction accuracy, as measured by a variable importance score (Figure 
17B). Examination of partial plots, which adjusts for the effects of other variables in the 
model, reveals that likelihood of response increases with low IFIT1/MX1 expression and 
high nsSNV load (Figure 17C). These relationships are further demonstrated in a scatter 
plot whereby the majority of patients that responded (blue circles) distribute to the lower 
right quadrant, representing high nsSNV load and low IFIT1/MX1 expression (Figure 17D). 
Accordingly, these patients also generally have a higher OOB predicted likelihood of 
response (larger circles). 
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Because of high correlations between IFIT1/MX1 with the multiple genes originally 
examined for IFN-driven resistance (Figure 17E and 9H), we used bootstrapping and 
previously described variable selection methods189 to better assess performance of 
IFIT1/MX1 and nsSNVs against these other TCIRs, TCIR ligands, and ISGs. This revealed 
that nsSNVs and IFIT1/MX1 are the most frequently selected variables among bootstrap 
samples, suggesting that they robustly associate with response (Figure 17E, right). 
Interestingly, IFN-I is also frequently selected, has a high importance score relative to the 
other genes, and negatively correlates with anti-PD1 response (Figure 17F). In total, these 
results provide correlative clinical evidence that high expression of IDILS genes and IFN 
signaling associate with progression to anti-PD1. 
Discussion 
Several clinical observations reflect the complex biology of IFN signaling in 
immunotherapy184. A major source of IFNG in the tumor microenvironment is T cells145. 
Since T cell infiltration is essential to generate an anti-tumor response, IFNG-related gene 
expression can correlate with response to immunotherapy190,191. However, IFNG also 
regulates inducible expression of PDL1 on tumor and immune cells. Accordingly, with 
immunotherapy regimens that do not block the PD1/PDL1 pathway, PDL1 and ISGs can 
portend relapse109,192,193. In contrast, when regimens include anti-PD1/PDL1, the presence 
of PDL1 and IFNG-related genes can favorably predict response due to the effectiveness 
of these agents at inhibiting PD1 activation. However, for a majority of patients, anti-
PD1/PDL1 does not appear sufficient despite having PDL1/IFNG-expressing tumors177. 
Our study reveals that this can result from PDL1-independent adaptive resistance 
associated with distinct TCIR ligands, ISGs, and IFN-I gene expression. In total, these 
clinical observations highlight how IFNs can track with favorable immune parameters, but 
yet orchestrate PDL1-dependent and PDL1-independent immune suppression.  
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Our data suggest that the development of PDL1-independent resistance is 
influenced by the nature and duration of IFN signaling in the tumor microenvironment. 
Adequate early production of type I IFNs promotes dendritic cell activation and T cell 
cross-priming183. IFNG signaling on host and tumor cells can also be important early 
during immune activation, particularly in tumors with limited baseline MHC-I expression194. 
However, our data support the notion that sustained IFN signaling contributes not only to 
PDL1 expression but also to PDL1-independent adaptive resistance. Mechanistically, 
prolonged IFNG signaling changes how tumor cells epigenetically respond to in vivo 
signals. STAT1 occupancy appears to associate with these epigenomic differences and 
is responsible for elevated expression of cancer-related ISGs and multiple TCIR ligands 
on resistant tumors. Interestingly, STAT1 has been shown to increase after persistent IFN 
stimulation to maintain a subset of ISGs including IFIT1 and MX1195. Given the extensive 
number of type I, II and III IFNs, multiple members from this large family may have similar 
or distinct effects. Thus, the nature of IFN signaling may regulate the balance between 
immune-mediated tumor elimination and escape, and when PDL1-independent adaptive 
resistance dominates over PDL1 alone.  
The ability of ICB to prevent or to reverse T cell dysfunction or exhaustion is 
thought to be an important pharmacological mechanism of action for these agents58. This 
is best defined in models of chronic infection where increasing antigen burden and 
duration of viremia results in the accumulation of PD1high TEX with elevated expression of 
multiple TCIRs and conversion from Eomes– to Eomes+. These PD1highEomes+ TEX with 
co-expression of multiple TCIRs are severely exhausted and have limited proliferative 
potential175. Thus, PD1 blockade preferentially reinvigorates PD1intEomes– TEX that are 
Tbet+ to give rise to PD1highEomes+ TEX178,196. Recent studies also demonstrate that a 
PD1+CXCR5+ CD8 T cell population that resides in lymphoid niches with low expression 
of inhibitory receptor ligands like PDL1 are targets for reactivation by PD1 blockade179,181. 
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Thus, given the heterogeneity of the TEX population, determining the TEX subset that is 
more responsive to ICB and/or devising approaches to reinvigorate deeply exhausted 
PD1highEomes+ TEX populations may be an effective strategy to improve response to 
immunotherapies. Addressing this notion, we show that in mice with ICB-resistant tumors, 
inhibiting tumor IFN signaling along with ICB increases the fraction of PD1highTCIRhigh 
Cl.5.3 and/or Cl.5.2 TEX that is Ki67+GzmB+ in both the tumor and periphery, consistent 
with reinvigoration of TEX and/or prevention of exhaustion. In contrast, T cells from TCIRlow 
clusters are less impacted. Moreover, knockout of tumor IFN signaling results in Cl.5.2 
and Cl.5.3 peripheral T cells that are almost exclusively Eomes+. In contrast, peripheral 
PD1highTCIRhigh Cl.5.2 and Cl.5.3 TEX from mice with intact tumor IFN signaling show more 
mixed Eomes status after ICB. Whether tumor IFNA/GRKO primarily promotes the 
conversion of reinvigorated Eomes– TEX to Eomes+ TEX in populations such as Cl.5.2, 
facilitates direct reinvigoration of Eomes+ TEX, or prevents the development of the 
exhausted state will require further investigation. Regardless, in mice with ICB-resistant 
tumors, blocking tumor IFN signaling can expand the T cell repertoire by preferentially 
increasing the proportion of PD1highTCIRhighEomes+ Ki67+GzmB+ T cells that otherwise 
would be severely exhausted (Figure 17G). 
Recently, two melanoma patients who initially responded to anti-PD1 but suffered 
late relapse were discovered to have mutations in JAK1 or JAK2101. In another study, 
melanoma patients who failed to respond to anti-CTLA4 were found to have copy number 
alterations in IFN pathway genes102. Together with the findings described here, these data 
suggest an emerging framework for resistance to ICB that consists of primary resistance, 
acquired resistance, and PDL1-dependent and PDL1-independent adaptive resistance. 
Primary resistance occurs due to selective pressures often related to tumor growth or 
survival that coincidently render cancers non-responsive to therapy. In contrast, acquired 
resistance occurs as a result of direct selective pressure imposed by treatment. Both are 
57 
 
often due to mutational or genetic events. The copy number loss in IFN pathway genes 
and mutations in JAK1/JAK2 represent loss-of-function (LOF) examples of primary and/or 
acquired resistance mechanisms to ICB. In both cases, it has been suggested that such 
genetic events may be selected to circumvent IFN-mediated cytostasis and 
cytotoxicity101,102, resulting in these tumors failing or relapsing after ICB due to reliance on 
IFN-regulated antigen processing or other positive immune effects. However, in contrast 
to LOF resistance mechanisms, adaptive resistance has been proposed to be a negative 
feedback response that antagonizes anti-tumor T cells though functioning IFNG signaling 
pathways, resulting in the upregulation of PDL1. These tumors, like the tumors used in 
this study, may be poorly responsive to the growth inhibitory effects of IFNs. Rather, 
prolonged IFN signaling enables STAT1-related changes to the in vivo epigenome and 
transcriptome that promote PDL1-independent adaptive resistance through IDILS. 
Whether IFN signaling is lost or retained may depend on the existence of other 
immune suppressive pathways or anti-cytostatic responses. Alternatively, rather than LOF 
and adaptive resistance mechanisms competing, an interplay between the two may exist. 
Our results demonstrate that type I and II IFNs can separately contribute to maintaining 
IFN-driven resistance. Therefore, an acquired JAK2 mutation may promote relapse yet 
still allow type I IFN to maintain PDL1-independent adaptive resistance. LOF mutations 
that affect both IFNAR and IFNGR signal transduction, such as a JAK1 mutation, may 
also influence ICB response and resistance in complex ways. For example, JAK1 LOF 
may promote on-going response to PD1 blockade and a long progression-free survival, 
as was reported in the patient harboring a JAK1 mutation101. However, the late clinical 
relapse in this same patient may reflect a critical issue on the durability of tumor responses 
when tumor eradication relies upon the reinvigoration of TEX. We show that IFNA/GRKO 
improves response of resistant tumors but preferentially expands T cells belonging to 
PD1highTCIRhighEomes+ T cell subsets. In chronic viral infection models, PD1 blockade of 
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PD1highEomes+ TEX fails to convert these cells into durable and self-renewing memory T 
cells197. Thus, a LOF JAK1 mutation may contribute to both initial response but also to late 
relapse should residual disease persist beyond the functional/proliferative capacity of 
reinvigorated PD1highTCIRhighEomes+ T cells that undergo preferential expansion when 
tumor IFN signaling is ablated. These opposing immunomodulatory effects of IFN 
signaling highlight a complex yet central role for this pathway in influencing ICB 
response184, which likely reflects why both LOF and IFN-driven resistance pathways exist. 
Combining different ICB agents with each other or other therapies is often empiric 
and can increase severe and life-threatening toxicity with unclear benefit in unselected 
patients198. Limiting the availability of multiple TCIR ligands by disrupting tumor IFN 
signaling may functionally block multiple TCIRs and serve as a general strategy to broadly 
target T cell inhibitory pathways. Besides the IDILS genes studied here, unidentified ISGs, 
and/or immune populations other than T cells may also promote IFN-driven resistance. A 
multigenic IFN-driven resistance program that goes beyond what we initially characterize 
in this study likely contributes to why interfering with tumor IFN signaling combined with 
ICB monotherapy is more effective than even quadruple antibody-based ICB. Thus, 
crippling a broad multigenic resistance program may help to address some of the 
challenges with formulating combination therapies. Practically, this may be accomplished 
with JAK inhibitors. The dose and schedule are likely critical and will need optimization, 
as indiscriminately blocking IFN signaling on host cells can interfere with the generation 
of anti-tumor183 and anti-viral responses149,151,199. Nonetheless, proper timing using a JAK 
inhibitor and biomarkers such as MX1 and IFIT1 to identify tumors under the influence of 
IFN-driven immune suppression may represent a feasible strategy for inhibiting PDL1-
independent resistance. 
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Figure 7: Prolonged tumor IFNG signaling is sufficient to instigate resistance to 
RT + anti-CTLA4, while type I and II IFN signaling maintains PDL1-independent 
resistance  
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Figure 7: A) Tumor volumes (day 17, split y-axis) and B) survival of mice with indicated 
tumors treated with RT + anti-CTLA4 (n=5-10). C) Standard (D5) and delayed treatment 
schedules for anti-CTLA4 + anti-PDL1. Sizes of B16 tumors prior to treatment for each 
schedule are shown (left). D) Tumor volumes for B16 tumors with or without IFNGRKO 
treated with anti-CTLA4 + anti-PDL1 according to indicated schedule. E) Tumor volumes 
relative to the average of untreated controls for B16 tumors with IFNGRKO or IFNA/GRKO. 
F) Survival of mice with Res 499 tumors with or without indicated KO, or G) after treatment 
with RT + anti-CTLA4 (n=5-10). H) Gene set analysis examining transcriptomic features 
associated with resistance to RT + anti-CTLA4, derived from comparing resistant B16 
tumors (e.g., Res 499) with parental tumors. Individual gene scores are on top along with 
an overall gene score and p-value. Heat map shows relative gene expression (columns) 
for sorted tumor cells with indicated KO (rows). Red is high expression and blue is low. I) 
Growth of JB2 tumors with or without IFNA/GRKO after RT + anti-CTLA4 (n=5-10). Unless 
indicated, error bars are S.E.M. of biological replicates. 
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Figure 8: Tumor IFN signaling drives PDL1-independent resistance 
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Figure 8: A) Survival after RT + anti-CTLA4 for mice with B16 tumors or tumors from B16 
cells chronically treated with type I IFNB (B16b) (n=5-10). B) PDL1 expression on Res 
499 cells after treatment with indicated doses of IFNL (µg/mL). C) Expression of PDL1 (an 
ISG responsive to type I and II IFN signaling) on B16 and B16 cells with IFNGR knockout, 
or D) B16 and B16 cells knocked-out for both IFNAR and IFNGR after treatment with IFNG 
or IFNG and IFNB, respectively. E) Tumor volumes prior to the start of treatment for each 
treatment schedule (Figure 2C). F) Tumor volumes after the indicated treatment schedule 
with anti-CTLA4 + anti-PDL1 for mice with B16 tumors or B16 tumors with IFNGR 
knockout or IFNGR and IFNAR knockout (IFNA/GRKO). G) Res 499 and Res 499 cells with 
IFNGR knockout after treatment with IFNG H) Res 499 and Res 499 cells with IFNAR 
knockout after treatment with IFNB. I) Res 499 and Res 499 cells with IFNAR and IFNGR 
knockout after treatment with IFNG and IFNB. J) Expression of PDL1 and TNFRSF14 on 
JB2 cells with IFNAR and IFNGR knockout after treatment with IFNB and IFNG. JB2 cells 
were derived from Res 499 PDL1KO cells. 
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Figure 9: STAT1 regulates a multigenic resistance program to ICB  
 
 
 
Figure 9: A) Protein levels of STAT1 after two weeks of in vitro IFNG treatment of B16 
cells followed by one-week washout (denoted B16γ). B) Principle components analysis of 
differential open chromatin regions (OCRs) from ATAC-seq of melanoma cells sorted from 
mice with the indicated tumors. C) Differential OCRs (rows) from B16γ vs. B16 (left) or 
Res 499 vs. B16 (right) are shown for all tumors (columns) color-coded (bottom of heat 
map) the same as the PCA plot. OCRs with predicted STAT1 binding sites are shown 
(black lines beside heat maps). D) Normalized coverage from ATAC-seq reads at base 
pair positions centered on STAT1 motifs. A fitted smoothing spline is shown for Res 499 
or B16γ (dark red) or B16 (blue). E) Tumor volumes (day 15, split y-axis) or F) survival of 
mice bearing Res 499 tumors with STAT1KO and/or PDL1KO after RT + anti-CTLA4 (n=10-
15). G) Correlation between Stat1 and the indicated genes from microarray analysis of 
whole tumor lysates. Blue dots indicate p<0.05. H) Heat map of gene correlation matrix 
with correlation value color-coded per the legend. I) Undirected ARACNE network graph 
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using TCGA human melanoma expression data. Edges are weighted by mutual 
information scores and nodes are color-coded by functional groups. J) Correlation 
between STAT1 and other genes in the network under conditions where PDL1 expression 
(x-axis) or CD8A expression (y-axis) is restricted to low/intermediate (left) or high (right) 
expression values. Blue dots indicate p<0.05. K) Gene set analysis of TCIRs, TCIR 
ligands, and ISGs. Individual gene scores are on top along with an overall gene score and 
p-value. Heat map shows relative expression of genes (columns) for sorted tumor cells 
with indicated KO (rows). Red is high expression and blue low. 
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Figure 10: Biological processes and epigenomic and transcriptomic changes 
regulated by tumor IFN signaling and STAT1 
 
 
Figure 10:   A) Expression of genes differentially expressed after IFNA/GRKO in Res 499 
versus control in the indicated melanoma cells sorted from in vivo tumors by flow 
cytometry. Also shown are Reactome gene sets with decreased (blue tones) or increased 
(red tones) expression after individual and combined IFN receptor knockout. Size of circles 
is proportional to number of genes, and circles are color-coded by p-value for statistical 
significance as indicated in the legend. Thickness of lines is proportional to genes shared 
between sets. B) Differential open chromatin regions by ATAC-seq with predicted STAT1 
binding sites were determined by de novo motif search and matching discovered motifs 
against the JASPAR database. Shown are representative top motifs, sequence logos, and 
e-values for matches against STAT1 consensus (bottom). Only motifs with an e-value < 
10–6 and a match to STAT1 ranking in the top 1% of transcription factor sites were 
considered. C) Quantitative gene set analysis for B16γ vs. B16 (left) or Res 499 vs. Res 
499 STAT1KO. Association between Stat1 expression and a previously described 
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resistance gene signature109 derived from comparing resistant B16 melanoma tumors 
(e.g., Res 499) with sensitive parental B16 tumors is analyzed for significance. The 
individual gene scores are indicated on top along with an overall gene score and p-value. 
Positive gene scores reflect positive correlation with Stat1. Bottom shows a heat map of 
the relative expression of each gene (columns) for each tumor type (rows). Red is high 
expression and blue is low. The dot plot on the right of the heat map indicates Stat1 
expression levels for each tumor. D) Expression of PDL1 after treatment with IFNG on 
Res 499 and Res 499 cells with STAT1 or STAT1 and PDL1 knockout.  
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Figure 11: Blocking IFN-driven resistance interferes with multiple TCIR ligands 
and improves response to ICB  
 
 
Figure 11: A) Expression of TCIR ligands on Res 499 cells after in vitro treatment with 
indicated type I or II IFN. B) Expression of TCIR ligands. Shown are representative 
histograms and MFI values from biological replicates. Isotype controls are shown in 
histograms on top. C) Gene set analysis of TCIRs, TCIR ligands, and ISGs. Individual 
gene scores are on top along with an overall gene score and p-value. Heat map shows 
relative expression of genes (columns) for sorted tumor cells with indicated KO (rows). 
Red is high expression and blue low. D) Survival of mice bearing Res 499 tumors with 
indicated KO after RT + anti-CTLA4 (n=20). E) Tumor growth and F) survival of mice with 
Res 499 tumors treated with anti-CTLA4 + anti-PDL1 along with anti-LAG3 and/or anti-
TIM3 (n=5-15). For comparison with anti-CTLA4 + anti-PDL1, * p=0.02 and *** p<0.001. 
For quadruple ICB vs. anti-CTLA4 + anti-PDL1 + anti-LAG3, p<0.01. G) Survival of mice 
with Res 237 ICB-resistant breast cancer tumors treated with indicated ICB (n=5-10). H) 
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Tumor growth and survival of mice bearing Res 499 tumors with or without IFNA/GRKO 
after anti-CTLA4 + anti-PDL1 (n=5). 
Figure 12: T cell inhibitory receptor ligands and identifying distinct exhausted T 
cell populations involved in IFN-driven resistance 
 
 
 
Figure 12: A) Expression of TNFRSF14 after treatment with IFNG on Res 499 cells with 
TNFRSF14 and PDL1 knockout. B) Schematic of rationale and strategy for identifying 
distinct T cell populations based on co-expression patterns of T cell inhibitory receptors 
(TCIRs) in order to determine if severely exhausted T cells expressing high levels of 
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multiple TCIRs (yellow) can preferentially expand when ligand expression on tumor cells 
is disrupted by inhibiting tumor IFN signaling. 
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Figure 13: Inhibiting IFN-driven resistance preferentially expands distinct 
populations of TEX  
 
Figure 13: A) Feature summary of nine populations (clusters) of CD44high CD8 peripheral 
T cells identified using co-expression of six TCIRs. Heat map shows the scaled MFI (rows) 
characterizing each cluster (columns). Clusters are additionally categorized (bottom 
boxes) by TCIR and PD1 status (see legend). Baseline frequency of T cells in each cluster 
compared to total splenic T cells (box plot) and frequency of Ki67high T cells is also shown 
(black box indicates too few events). B) Co-expression of the six TCIRs on T cells 
belonging to the PD1highTCIRhigh clusters Cl.5.2 and Cl.5.3. C) Percentage of CD8 TILs 
that are Ki67+GzmB+ from Res 499 tumors with or without IFNA/GRKO grouped by anti-
CTLA4 + anti-PDL1 treatment (ICB). D) Distribution of Ki67+GzmB+ CD8 TILs in each 
TCIR cluster, and E) percentage of Ki67+GzmB+ T cells in each TCIR cluster. F) 
Representative contour plots of PD1 and Eomes expression (red), and Ki67 and GzmB 
expression (blue), from CD8 TILs belonging to the PD1highTCIRhigh Cl.5.2 cluster. G) 
Percentage of indicated peripheral PD1+ T cells over time. ICB was given at day 13. H) 
Pie chart summarizing the average frequency of PD1+ CD8 peripheral T cells in each TCIR 
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cluster. I) Day 20 percentage of Eomes+ Ki67+GzmB+ T cells in each TCIR cluster after 
ICB. J) Representative contour plots and K) summary of Eomes and Ki67/GzmB status in 
T cells from the indicated TCIR clusters at day 20. Ki67/GzmB analysis is restricted to the 
Eomes+ population from each cluster. Unless indicated, error bars are S.E.M. of biological 
replicates. 
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Figure 14: T cell population identified by model-based clustering of T cell 
inhibitory receptors 
 
 
 
Figure 14: A) Co-expression of six T cell inhibitory receptors (TCIRs) for seven of the nine 
TCIR clusters identified on splenic CD8 T cells by model-based clustering. See Figure 
11H. B) Pie chart summarizing the average frequency of TRP2+ CD8 TILs in each TCIR 
cluster for Res 499 and Res 499 IFNA/GRKO, or C) Res 499 and Res 499 STAT1KO.  
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Figure 15: Disrupting IFN-driven resistance renders highly multi-ICB resistant 
tumors sensitive to ICB monotherapy  
 
 
Figure 15: A) Tumor growth of Res 499 tumors with the indicated IFN receptor KO after 
anti-PD1 (left) or anti-CTLA (right) (n=5-10). *** p<0.001 for comparisons with Res 499. 
For anti-CTLA4 (right), p=0.037 for IFNA/GRKO vs. IFNGRKO. B) Effect of IFN receptor KO 
on survival of mice with Res 499 tumors or C) Res 237 ICB-resistant breast cancer tumors 
treated with anti-CTLA4 (n=5-10). D) Contour plot of indicated TCIR ligands in Res 499 
tumors from mice after treatment with a JAK inhibitor (JAKi). Red contours represent 
melanoma cells and blue indicate CD45+ immune cells. Statistical summary from 
biological replicates is shown on right. E) Treatment schedules for anti-CTLA4 and JAKi. 
F) Tumor growth curves of Res 499 tumors from each treatment schedule (D8, n=10; D5, 
n=7). G) Tumor growth of Res 237 breast cancer tumors treated with anti-CTLA4 and/or 
JAKi for five days starting on day 10 (n=6). Unless indicated, error bars are S.E.M. of 
biological replicates.  
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Figure 16: Improved response after blocking tumor IFN signaling is CD8 T cell 
dependent 
 
 
 
Figure 16: A) Heat map of the relative RNA-seq expression of the indicated TCIR ligands 
and ISGs from parental TSA breast cancer or Res 237 cells. Res 237 cells are from a TSA 
tumor that relapsed after RT + anti-CTLA4. B) Mice with Res 499 IFNAR/IFNGR knockout 
tumors were treated with anti-CTLA4 with or without anti-CD8 to deplete CD8 T cells. 
Shown is a representative density plot of CD8 vs. CD4 T cell frequency in the tumor (box 
indicates frequencies of CD8 T cells as a percentage of CD45+) and C) tumor growth 
curves (n=5). D) Representative histogram and E) strip plot of in vivo mean fluorescence 
intensity for MHC class I expression on melanoma cells from Res 499 tumors and Res 
499 tumors with IFNAR/IFNGR knockout. F) Relative expression of MHC class I, 
immunoproteosome subunits, TAP, IFN receptor, and IFN genes (rows) in human 
melanoma and breast cancer cell lines (columns) from the Cancer Cell Line Encyclopedia 
(CCLE). Data are normalized but not centered and expression is color-coded as indicated 
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in the legends. White empty cells indicate absence of expression. G) Statistical summary 
from biological replicates of TCIR ligands in Res 499 tumors from mice after 4 days of 
treatment with a JAK inhibitory (JAKi) or control.   
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Figure 17: ISGs associated with IFN-driven resistance can predict clinical 
response to anti-PD1 
 
 
 
Figure 17: .A random forest model for melanoma response/progression after anti-PD1 
was developed using the number (Log10) of nsSNVs and the average mRNA expression 
of IFIT1 and MX1 (IFIT1/MX1) for a cohort of 27 patients. Shown are A) overall error rates, 
error rates for progression or response, and B) variable importance scores (greater than 
0 is deemed significant) determined from out-of-bag (OOB) samples. Error bars represent 
Monte Carlo standard deviations. C) Partial plots showing the adjusted effects of the 
indicated variables on the probability of response. Red dashed lines are standard errors. 
D) Predicted probabilities of response from OOB samples as a function of IFIT1/MX1 and 
nsSNVs. Larger circle sizes represent higher probability (legend). Actual response (blue) 
and progression (red) are denoted by circle color. Quadrants are divided by values from 
partial plots approximating 50% probability of response. E) Association between 
IFIT1/MX1 and nsSNVs with clinical response to anti-PD1 compared to other genes. Gene 
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expression correlation is shown in the heat map (left). The frequency of bootstrap samples 
that each variable was selected as significant for predicting response and its variable 
importance are plotted (right). Grey dotted line for each axis is the upper 5% quantile. Top 
variables are highlighted in blue and IDILS TCIR ligands in red. F) Partial plot representing 
the adjusted effects of IFN-I on the probability of response. Red dashed lines are standard 
errors. G) Model for IFN-driven resistance. 
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS 
 
PD-L1 Mediated Resistance  
 
The importance of the PD1/PD-L1 signaling axis in determining response to 
immune checkpoint blockade has been well established.  Here we show that tumor cells 
expressing PD-L1 is the dominant mediator of resistance to anti-CTLA4+RT in mouse 
models of both metastatic melanoma and breast cancer.  PD-L1 expression by tumor cells 
was more important in mediating resistance in our primary B16 and TSA tumors as 
opposed to the relapsed resistant 499 and 237 tumors.  In addition to expression of PD-
L1 by the tumor, high levels of PD-L1 were also observed in certain tumor infiltrating 
lymphocytes, principally tumor associated macrophages200.  In primary tumors, this PD-
L1 on immune cells seems less important in mediating resistance than in relapsed ICB 
resistant tumor lines, although this needs to be studied more closely as a small effect 
could be lost given the strong effect of knocking out PD-L1 in the tumor cells in these 
parental tumor lines.  One way to further evaluate the role of immune PD-L1 is by 
implanting tumors into PD-L1 knockout mice161.   
Macrophages are PD-L1 high in both parental and relapse tumors and depleting 
them using anti-CSF1R in resistant tumors improves response to anti-CTLA4+RT.  
However, it remains unclear if this benefit is through loss of a major expresser of PD-L1 
in the tumor microenvironment, or through some other function of the macrophages.  The 
macrophages in these tumors were predominantly of the immunosuppressive M2 
phenotype so they could have been inhibiting the immune response in a PD-L1 
independent manner.  Anti-CSF1R antibodies have previously been shown to be effective 
in depleting tumor associated macrophages and increasing the CD8+/Treg ratio167,201.  The 
chemotherapeutic agent Trabectedin has also been shown to rapidly induce apoptosis 
only in mononuclear phagocytes202.  These offer exciting therapeutic options to potentially 
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synergize with immune checkpoint blocking antibodies to improve the anti-tumor 
response.  Further study on how the macrophages are inhibiting the immune response by 
utilizing conditional knockouts of PD-L1 in macrophages or adoptively transferring PD-L1 
null macrophages into CD11b-DTR mice would be critical to understanding whether it is 
PD-L1 expression or polarization that is modulating the immune response.   
The importance of PD-L1 in both the tumor and immune compartments in 
modulating resistance was also confirmed in our clinical trial of anti-CTLA4+RT.  Patients 
who had high PD-L1 staining on their tumor, macrophages, or both responded poorly to 
treatment.  Similar results have been reported by other groups, with high PD-L1 staining 
predicting worse response to anti-CTLA4 monotherapy91.  Unlike in our models, it is less 
well defined whether tumor or immune PD-L1 is more important in predicting response in 
patients.  One of the main issues with comparing results across trials is that there is no 
unified standard for defining PD-L1 staining intensity, making it difficult to compare results 
across trials.  Additionally, macrophages are generally not subset with additional markers 
making it challenging to know what role macrophage polarization plays in ICB resistance, 
regardless of whether the macrophages are PD-L1 positive or not.  While PD-L1 seems 
to be a critical mediator of resistance especially to anti-CTLA4, there is also PD-L1 
independent resistance as illustrated by the patients on our clinical trial of anti-CTLA4+RT 
who progressed and went on to further progress on anti-PD-1 regardless of the PD-L1 
status of their tumor.  Additionally, the differential effect of knocking out PD-L1 in primary 
versus relapse tumors also suggests that over the course of an immune response tumor 
cells may acquire additional PD-L1 independent resistant mechanisms consistent with the 
idea of adaptive immunity168,200. 
STAT1/Interferon Mediated Changes in Parental and Relapse Cell Lines 
 
While PD-L1 signaling is one of the most well-studied resistance mechanisms in 
immunotherapy, and one of the dominant mediators of resistance in our model, our results 
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also implicate additional PD-L1 independent resistance mechanisms.  499 PD-L1 
knockout tumors that relapsed over 40 days after initial treatment with anti-CTLA4+RT 
(JB2) were completely resistant to treatment when transplanted into naïve mice.  The loss 
of neo-antigens through immunoediting is one possible PD-L1 independent resistance 
mechanism, but our resistant cell lines have lost very few predicted neo-antigens 
compared to their respective parental cell lines by exome-seq.  Interferon signaling 
through STAT1 drives PD-L1 and other inhibitory pathways in multiple cell types109,145, and 
knocking out interferon signaling in JB2s dramatically resensitized them to treatment, 
suggesting interferon driven resistance is the major PD-L1 independent resistance 
mechanism in our model.  In our mouse models of primary and relapsed melanoma and 
breast cancer both type I and type II interferons are capable of inducing PD-L1 expression 
as well as the expression of multiple other CD8+ T cell inhibitory ligands200.   
Despite these commonalities between the parental and relapsed cell lines, 
knocking out STAT1 or the interferon receptors had divergent effects in our parental 
versus relapsed cell lines.  Loss of STAT1 led to worse response to anti-CTLA4+RT or 
anti-PD1 monotherapy in parental B16 or TSA but improved response in the 499 and 237 
relapsed lines.  One reason for this differential response is likely chronic interferon 
exposure during the relapse process.  After B16 tumors are treated with anti-CTLA4+RT 
interferon gamma is produced in high enough quantities to be detected in the peripheral 
blood by ELISA.  In vitro treatment of B16 cells with low levels of interferon gamma for 3 
weeks was sufficient to render them resistant to anti-CTLA4+RT when they were injected 
into mice.  Interferon signaling through STAT1 has also been shown to orchestrate 
chromatin remodeling203; we observe changes in chromatin openness at STAT1 binding 
sites in 499 compared to B16 by ATAC-seq suggesting these changes could be promoting 
resistance.  One outstanding question is how these chromatin changes correlate with 
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transcriptional changes that mediate the differential response to immune checkpoint 
blockade between primary and relapsed tumors. 
Clinical trials taking pre- and post-treatment biopsies from patients receiving 
immune checkpoint blockade have focused on transcriptomic changes or antigenic shifts 
through RNA-seq or Exome-seq.  There is little available information on possible 
epigenetic changes that could be occurring over the course of treatment and exposure to 
interferon or other signals that could lead to chromatin remodeling.  These epigenetic 
changes could prove important in predicting response especially in patients with a large 
immune infiltrate whose tumors could have already been chronically exposed to interferon 
even before treatment.  Identifying what chromatin changes correlate with 
response/resistance to immune checkpoint blockade in paired pre-clinical models of 
parental and relapsed tumors is an important first step.  One potential way to combat these 
epigenetic changes would be through inhibitors that alter how proteins interact with 
chromatin such as JQ1204.   Blocking transcription through the newly open STAT1 binding 
sites in the relapsed tumors with a drug such as JQ1 could potentially reverse resistance 
and should be evaluated as a possible adjuvant therapy in our relapsed models. 
Interferon Signaling Regulates Response in Resistant Tumors 
 
Inhibiting interferon signaling by knocking out either the type I, type II, or both 
interferon receptors dramatically resensitized resistant tumors to single agent immune 
checkpoint blockade.  This improved response was accompanied by a significant 
expansion of tumor reactive CD8+ T cells that had high expression of multiple inhibitory 
ligands are generally considered terminally exhausted (Figure 18).  In addition to a 
numeric expansion, these inhibitory ligand high T cells also had increased levels of 
Granzyme B and Ki67 suggesting that they were reinvigorated.  These findings suggest 
the ability to uncouple exhaustion from response by targeting inhibitory ligands in the 
tumor en masse through blocking interferon signaling.  As knocking out the interferon 
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receptors in patients would be challenging, we also showed that administering a clinically 
available JAK inhibitor to mice with wild-type tumors also dramatically resensitized them 
to single agent ICB.  Translating this finding into patients requires identifying the proper 
timing of ICB and JAK inhibitor administration as inhibiting interferon too early can 
completely abrogate the immune response183.  In mice, multiple deeply exhausted T cell 
populations expand after ICB in tumors without interferon signaling.  Identifying which 
populations are most important for response by sorting them out of tumors and doing in 
vitro functional assays will be important in identifying biomarkers that the combination of 
JAKi and ICB is working in patients.   
We have identified more than five known inhibitory ligands regulated by interferon 
signaling in our mouse models.  The role of PD-L1 as one of the primary drivers of 
resistance has already been established in our model but further work is needed to isolate 
the contribution of the other ligands.  Individual knockouts or overexpression of each of 
these ligands is important to identify which interferon driven inhibitory ligands are 
important for predicting response to ICB.  Paired with any epigenetic markers of resistance 
from the ATAC-seq, looking for expression of the identified ligands in patient tumors would 
enable more accurate identification of patients who would benefit from the JAK inhibitor.   
Our preliminary work using either anti-CTLA4 or anti-PD1 monotherapy in IFNAR 
or IFNGR knockout tumors has identified differences in response to each ICB in each 
IFNR KO tumor.  Consistent with prior observations, type I and type II interferons have 
overlapping and distinct effects on the cells and these effects appear to pertain to ICB 
response as well.  Deconvoluting proteomic, transcriptomic, or epigenetic signatures 
associated with exposure to type I, type II, or both types of interferon will likely be important 
in choosing which ICB to combine with the JAK inhibitor, as well as possibly more specific 
inhibitors blocking either type I or type II interferon signaling.  The differential regulation of 
ISGs by type I and type II interferon may also differentially affect the T cell response or 
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implicate additional immune subtypes in the response.  For example, type II IFN drives 
class I MHC expression in our models and therefore blocking IFNGR could lead to NK cell 
involvement through missing self.  Additionally, many T cell inhibitory receptors are also 
expressed on other immune subtypes such as NK cells and loss of the inhibitory ligands 
on the tumors could allow these cells to participate in the immune response as well.  
Identifying the relative contributions of type I and type II interferon signaling to different 
types of ICB resistance is an important step in identifying which patients will benefit from 
a JAKi or other methods of blocking interferon signaling in the tumor.   
  
84 
 
Figures 
 
Figure 18: Model of Interferon-Driven Resistance to Immune Checkpoint Blockade 
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CHAPTER 5: MATERIALS AND METHODS 
 
Experimental Model and Subject Details 
Mice 
All animal experiments were performed according to protocols approved by the 
Institutional Animal Care and Use Committee of the University of Pennsylvania.  Five to 
seven week old female C57BL/6 (Stock# 027), BALB/c (Stock# 028), were obtained from 
Charles River Laboratory.  Five to seven week old female C57BL/6 (Stock# 000664) and 
IFNy KO (B6.129S7-Ifngtm1Ts/J –Stock# 002287) were obtained from Jackson 
Laboratory (Bar Harbor, ME).  Mice were maintained under pathogen-free conditions. 
Human 
The clinical trial of RT and anti-CTLA4 for metastatic melanoma patients 
(NCT01497808) has been described in detail109. The study protocol was approved by the 
University of Pennsylvania institutional review board. All participating patients provided 
written informed consent. 
Cell Lines 
B16-F10 melanoma cells, TSA breast cancer cells, and resistant sublines were 
derived and cultured as previously described109.  
Method Details 
Immunohistochemistry for PDL1 
Details on PDL1 staining of formalin-fixed, paraffin-embedded tumors collected at 
the time of surgical resection or from biopsy have been described109. In brief, intensity of 
staining on a 0-3+ scale, the percent positive staining on tumor cells or macrophages 
(identified by H&E and morphological features), and the cellular pattern (membrane vs 
cytoplasm) were independently analyzed by two pathologists. 
CRISPR gene targeting 
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Gene targeting by CRISPR/Cas9 was accomplished by co-transfection of a Cas9 
plasmid (Addgene, 41815), the guide sequence (selected using ZiFit Targeter) cloned into 
the gBlock plasmid, and a plasmid with the puromycin selection marker. Gene blocks used 
contain a 20 bp target size (N), U6 promoter, gRNA scaffold, and termination signal. The 
sequence and sequences for each guide used are listed in Supplemental Table 1. 
Successful targeting of the gene(s) of interest was determined by treating cells with and 
without 100 ng/mL of interferon (IFN)-gamma (PeproTech), 1000 units/mL IFN-beta (PBL 
Assay Science), or both depending on the target gene, and examining PDL1 and 
TNFRSF14 surface expression by flow cytometry. Knockout cells were sorted from a bulk 
knockout population using Fluorescence Activated Cell Sorting (FACS) on the Aria (BD) 
or FACSJazz (BD) to maintain the diversity of the parent cells.  
In vivo mouse studies 
Tumor injection and treatment schedule were done as previously described109. 
Blocking antibodies were given on days 5, 8, and 11 unless otherwise specified. Anti-CD8 
was given on days -2, 0, 4, 8, 12, and 16. Anti-CSF1R was given every 3 days starting on 
day 5. For in vivo experiments CTLA4 (9H10), PDL1 (10F.9G2), PD1 (Merck mDX400), 
CD8 (2.43), and Lag3 (C9B7W), and were all administered intraperitoneally at 200 
ug/dose. TIM3 (BE0115) was given at 250 ug/dose, and CSF1R (AFS98) was given at 1 
mg/dose. Ruxolitinib was administered intraperitoneally at 60 mg/kg. Isotype controls were 
used to confirm the lack of non-specific effects and a similar response and survival to 
untreated mice. 
Flow cytometry 
Spleen and tumor were harvested at day 15 post tumor implantation. Single-cell 
suspensions were prepared and red blood cells were lysed using ACK Lysis Buffer (Life 
Technologies). Live/dead cell discrimination was performed using Live/Dead Fixable Aqua 
Dead Cell Stain Kit (Life Technologies). Cell surface staining was done for 30 min at 4 
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degrees. TRP2 and Ova tetramer (MBL International) staining was done at 37 degrees for 
90 minutes and then surface antibody staining was performed. Intracellular staining was 
done using a fixation/permeabilization kit (eBioscience). All data acquisition was done 
using an LSR II (BD) or FACSCalibur (BD) and analyzed using FlowJo software (TreeStar) 
or the FlowCore package in the R language and environment for statistical computing. 
ELISA 
Mice were treated with anti-CTLA4 on days 5, 8, 11 and 20 Gy RT to the right 
tumor on day 8. Peripheral blood was collected on days 3, 6, 10, 14, and 17, and plasma 
was centrifuged at 850 x g for 10 minutes. Supernatants were frozen in aliquots and 
subsequently analyzed by ELISA for mouse IFN alpha (Affymetrix), beta (PBL Assay 
Science), and gamma (Life Technologies) according to manufacturer’s instructions. 
RNA-Seq of sorted mouse tumors 
Mice were injected with tumors as previously described.  On day 15 tumors were 
harvested, red blood cell lysis was performed, and a single cell suspension was created. 
Tumor cells were stained with Live/Dead Aqua and CD45. Samples were sorted on an 
Aria (BD) by gating on live, CD45 negative cells. Total RNA was isolated and purified from 
the cells using Isol-RNA Lysis Reagent (Fisher) and treated with DNase I (Fisher). RNA-
seq libraries were prepared using the TrueSeq Stranded Total RNA Library Prep Kit 
(Illumina) and sequenced on Illumina HiSeq 2500 with 100 base paired end reads.  
ATAC-Seq of sorted mouse tumors 
ATAC-seq libraries were prepared as described previously205. Approximately 
200,000 sorted tumor cells were used for each library using the same sort methodology 
as RNA-seq. Libraries were sequenced on Illumina HiSeq 2500 with 100 base pair end 
reads.  
Exome-Seq of mouse melanoma cell lines 
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Genomic DNA was isolated and purified from tumor cell lines in vitro using Purelink 
Genomic DNA Kit (Fisher) and exome libraries were prepared using the SureSelectQXT 
Kit (Agilent) with SureSelectXT Mouse All Exon bait. Libraries were sequenced on an 
Illumina HiSeq 2500 with 100 base paired end reads. Reads were trimmed with 
AgilentReadTrimmer (Agilent) and then aligned to GRCm38 reference genome using 
BWA v0.7.12 (Li and Durbin, 2009) with the bwa-mem algorithm. Aligned reads were 
deduplicated with Picard Tools and processed using GATK v3.3.0 (McKenna et al., 2010). 
Variants were called using the GATK Unified Genotyper and hard filtered with filters 
according to GATK best practices recommendations (Van der Auwera et al., 2013; 
DePristo et al., 2011): QD < 2.0; MQ < 40, FS > 60, MQRankSum < -12.5 and 
ReadPosRankSum < -8. Variants were annotated using the VariantAnnotation R package 
version 1.16.4 (Obenchain et al., 2014). Losses of heterozygosity (LOH) mutations were 
defined as an allele frequency of less than 0.02 in the Res 499 cell line but higher than 
0.02 in the parental B16 cell line. Variants found in transcripts with no evidence of RNA 
expression by RNA-seq were filtered out. Eight to 10-mer peptides surrounding each non-
synonymous mutation were extracted and their H-2Kb and H-2Db MHC-I binding affinities 
were predicted using IEDB (http://www.iedb.org) using the ANN algorithm. Peptides were 
then assessed for a predicted affinity of 500 nM or less and 50 nM or less. 
Quantification and Statistical Analysis 
Analysis of tumor volume, growth curves, and survival curves 
Mice were randomly assigned a treatment group and tumor volume determined by 
caliper measurements. Differences in survival were determined for each group by the 
Kaplan-Meier method and the overall p-value was calculated by the log-rank test using 
the survival R package version 2.38-3. For mouse studies, an event was defined as death 
or when tumor burden reached a pre-specified size to minimize morbidity. A mixed effect 
linear model using the lmerTest R package version 2.0 was used to determine differences 
89 
 
in growth curves.  The significance of all two-way comparisons was determined by two-
sample, two-tailed t-test. For non-parametric data, a Wilcoxon or Mann-Whitney test was 
used. Significance of tumor growth was determined by a mixed effect linear model. Simple 
correlation between variables was done using a Spearman correlation. 
Analysis of RNA-seq of sorted mouse tumors 
Reads were trimmed first using cutadapt v1.9206 with parameters -q 10 -m 30 -O 
4. Trimmed reads that were aligned to rRNAs sequences were removed and the remaining 
sequences were aligned to the GRCm38 reference genome using STAR v2.4.0k207 with 
parameters --outFilterMultimapNmax 100 --outFilterMismatchNmax 999 --
outFilterMismatchNoverLmax 0.06. Primary aligned reads were counted against 
GENCODE annotation vM4 (Mudge and Harrow, 2015) using Subread v1.4.6208 with 
parameters -s 2 -minReadOverlap 10. The DESeq2 R package version 1.10209 was used 
for differential gene expression analysis. 
Analysis of ATAC-seq of sorted mouse tumors 
Reads were trimmed using cutadapt v1.9 with parameters -m 30 -O 4, and mapped 
to the reference genome using bowtie2 v2.2.4210 with parameters --fr --no-mixed --no-
discordant --X 2000. Reads were then deduplicated with Picard Tools v1.140. Secondary 
alignment and low quality reads (mapQ <= 10) were filtered out and all reads aligning to 
the plus strand were offset by +4 bp, and all reads aligning to the minue strand were offset 
−5 bp205. Peaks were called using MACS2 v2.1.0 (Feng et al., 2012) with parameters -f 
BAMPE --no-model and FDR cutoff 0.01. Regions overlapping with the ENCODE 
“blacklist” were removed. The DiffBind R package version 1.16 (Ross-innes et al., 2012) 
was used for differential binding analysis with a false discovery rate of 0.10. The rGADEM 
R package version 2.18 was used for motif discovery. Discovered motifs were then 
matched against the JASPAR database. Only motifs with an e-value < 10–6 and had a 
STAT1 binding site ranking in the top 1% of all transcription factors examined were kept. 
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For DNA footprinting, open chromatin regions (OCRs) were scanned for transcription 
factor footprinting using Wellington (Piper et al., 2013) with p-value cutoff -10. Identified 
footprinted regions were then extended 5bp on each side and scanned for STAT1 motifs 
using FIMO (Grant et al., 2011) with default settings and Position Frequency Matrices 
(PFMs) from the JASPAR database. Mapped reads from replicates were merged and the 
transposon cutting positions (5’ end of mapped reads) were counted around the identified 
motifs. Counts were normalized to the total insertion sites in OCRs. 
Analysis of mouse and human genes associated with STAT1 
Using either mouse microarray data for Res 499 and B16 tumors or patient 
melanoma data from TCGA, the strength of the correlation between STAT1 and genes 
from a manually curated gene list that included previously described cancer-associated 
ISGs (IFI44, IFIT1, IFIT3, ISG15, MX1, OAS1)140, T cell inhibitory receptors (TCIRs), TCIR 
ligands, and other IFN regulated immune suppressive mediators such as IDO1 was 
determined by calculating a Spearman correlation coefficient along with the associated 
two-sided p-value. For the mouse data, microarray expression values from Res 499 and 
B16 tumors were examined separately and the correlation between STAT1 and each gene 
compared between these groups. For TCGA human melanoma data, additional genes 
were added to the gene list as a surrogate for T cell infiltration, including CD8A, PRF1, 
and GzmA. In order to analyze which genes most strongly influence STAT1, a gene 
network was constructed using ARACNE, as implemented in the minet R package version 
3.28211. Using the resulting mutual information matrix, an undirected graph was 
constructed with edges weighted by the mutual information scores. Based on the network 
findings, CD8A and PDL1 mRNA expression values were divided into q-quantiles, where 
q = 6, in order to examine how perturbing each of these genes, which formed strong 
connections with STAT1, would influence the correlation between STAT1 and other genes 
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in the network. Specifically, within each quantile for CD8A or PDL1, the correlation 
coefficients and p-values between STAT1 and other genes in the network were compared. 
Gene set enrichment analysis 
To test whether gene sets were enriched in response to different conditions, we 
utilized Gene Set Analysis as implemented in the GSA R package version 1.03212 or the 
piano R package. For GSA, the “maxmean” test statistic was used to test enrichment using 
a two-class comparison when comparing groups or quantitative analysis for continuous 
variables. All p-values and false discovery rates were based on 500-1000 permutations. 
For restandardization, a method that combines randomization and permutation to correct 
permutation values of the test statistic and to take into account the overall distribution of 
individual test statistics, the entire data set was used rather than only the genes in the 
gene sets tested. Gene signatures examined included a manually curated list of TCIRs, 
TCIR ligands, and ISG (Figure 3H) and the upregulated genes from a resistance signature 
for radiation and anti-CTLA4109. For the piano implementation, Reactome gene sets were 
downloaded from the Molecular Signatures Database v5.1 
(http://software.broadinstitute.org/gsea/msigdb). 
Random forest for classification and survival analysis 
Random forest (RF) for classification, regression, and survival analysis is a 
multivariable non-parametric ensemble partitioning tree method that can be used to model 
the effect of all interactions between genes on a response variable213. Each model was 
constructed using approximately two-thirds of randomly selected samples and cross-
validated on the one-third of the samples left out of the model building process (out-of-bag 
samples). After many iterations, results of all models were averaged to provide unbiased 
estimates of predicted values, error rates, and measures of variable importance. 
Performance of an RF model was measured by the misclassification error rate for 
classification and by a concordance index (one minus the error rate) for survival. For each 
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gene, an importance score was determined, which measures the contribution of the 
variable to the error rate (higher scores are more predictive). We used the 
randomForestSRC package version 2.0.7189 and the following parameters: 1000 trees, 
node size of 2, and mtry values equal to the number of variables in the model. The default 
splitting rule was used for classification and the log-rank slitting rule was used for survival 
analysis. For small sample sizes, 500 Monte Carlo replications were used and the results 
averaged. All predicted values, error rates, and importance scores were based on cross-
validation using out-of-bag samples to provide unbiased estimates. To examine the effect 
of sampling error on variable selection, 1000 bootstrap samples were utilized and variable 
selection was performed using the minimal depth statistic189. 
T cell inhibitory receptor expression analysis 
To determine the patterns of T cell inhibitory receptor expression, splenic T cells 
were isolated from mice bearing Res 499 or Res 499 IFNAR/IFNGR knockout tumors and 
processed for flow cytometry. Fluorescence intensity data were analyzed using the 
flowCore R package version 1.36.3 and transformed using the logicle method. After 
excluding debris, dead cells, doublets, and non-T cell populations using a dump channel, 
the CD44high CD8 T cell population was identified. From this population, T cells that were 
negative for all T cell inhibitory receptors (TCIRs) examined (PD1, LAG3, 2B4, TIGIT, 
TIM3, CD160) were excluded. From the remaining CD44high CD8 T cells, the expression 
of the TCIRs was used as features for model-based clustering as implemented in the 
mclust R package version 5.1. An ellipsoidal distribution, variable shape, variable 
orientation, and variable volume were used as model parameters. An aggregate data 
matrix from random sampling of 1000 to 5000 events from each sample was used for 
clustering analysis. The number of initial clusters was estimated based on the “elbow” 
from the Bayesian Information Criterion as a function of cluster number. Resulting clusters 
were then inspected and the within cluster sum of squares calculated. Cluster(s) with the 
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highest within cluster sum of squares and confirmed to be a persistently mixed population 
by inspection of scatter plots for all pair-wise combinations was then re-clustered using 
the same steps. This procedure resulted in nine TCIR clusters. Using cluster membership 
as class definitions, a random forest (RF) based classifier was developed using the same 
aggregate data matrix. This RF classifier had an out-of-bag error rate of less than 5% and 
was used to assign CD44high CD8 T cells from a new sample from either the periphery 
or the tumor to one of the nine TCIR clusters. 
Data and Software Availability 
Software 
PRISM was used for some basic statistical analysis and plotting 
(http://www.graphpad.com), while the R language and environment for statistical 
computing and graphics (https://www.r-project.org) was used for the majority of the 
statistical and bioinformatics analysis. The R packages used for various analysis 
described in the methods were obtained from Bioconductor 
(https://www.bioconductor.org) and/or from CRAN (https://cran.r-
project.org/web/packages/). Additional software and packages for processing, alignment, 
and analysis of sequencing data include: 
cutadapt (https://pypi.python.org/pypi/cutadapt) 
Subread (http://subread.sourceforge.net) 
bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml) 
Picard Tools (https://broadinstitute.github.io/picard/) 
MACS2 (https://pypi.python.org/pypi/MACS2) 
Wellington (https://pypi.python.org/pypi/pyDNase/0.2.3) 
FIMO (http://meme-suite.org/doc/fimo.html) 
 
Data Resources 
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The RNA and ATAC sequencing data has been deposited at the GEO 
(http://www.ncbi.nlm.nih.gov/geo) under the accession number GSE83850. 
Mouse microarray and human gene expression data 
Normalized Affymetrix GeneChip Mouse Gene ST Array data for B16 and Res 499 
tumors have been previously described109 and were used to examine expression of 
interferon and interferon receptor gene transcripts. Z-scores for mRNA expression data 
for melanoma patients from The Cancer Genome Atlas (TCGA) were obtained from 
cBioPortal (http://www.cbioportal.org). RMA normalized gene expression data for human 
melanoma and breast cancer cell lines were obtained from the Cancer Cell Line 
Encyclopedia (http://www.broadinstitute.org/ccle/home). Normalized transcriptomic data, 
summarized exome analysis, and annotations for human melanoma patients treated with 
anti-PD1 were previously described142 and downloaded from the GEO 
(http://www.ncbi.nlm.nih.gov/geo), accession GSE78220. When multiple probes existed 
for the same gene, the probe values were averaged. 
 
Additional Resources 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
H-2 Kb TRP2 Tetramer MBL International  T03015 
Anti-mouse CD8 MBL International D271-4 
Anti-mouse TIGIT BD Biosciences 565270 
Anti-mouse Ki67 BD Biosciences 563757 
Anti-mouse LAG-3 BioLegend 125219 
Anti-mouse 2B4  Life Technologies 553305 
Anti-mouse/human CD44 BioLegend 103031 
Anti-mouse TIM-3 BioLegend 119703 
Anti-mouse/human Granzyme B Life Technologies GRB17 
Anti-mouse PD1 BioLegend 109110 
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Anti-mouse Eomes eBioscience 50-4875 
Anti-mouse CD45.2 BioLegend 109822 
Anti-mouse CD8a BioLegend 100713 
Anti-mouse CD160 BioLegend 143008 
Anti-mouse B220 eBioscience 47-0452 
Anti-mouse CD4 eBioscience 47-0042 
Anti-mouse NK1.1 eBioscience 47-5941 
Anti-mouse CD3 BioLegend 100229 
Anti-mouse MHCII BioLegend 107631 
Live/Dead Aqua Life Technologies L34957 
Anti-mouse CD80 BioLegend 104731 
Anti-mouse CD86 BioLegend 105043 
Anti-mouse CD112 Abcam EPR6717 
Anti-mouse PD-L1 eBioscience 46-5982 
Anti-mouse Galectin9 BioLegend 136103 
Anti-mouse CD155 BioLegend 131511 
Anti-mouse HVEM BioLegend 136305 
Anti-mouse CD48 BioLegend 103431 
Anti-mouse F4/80 BioLegend 123114 
Anti-mouse CTLA-4 BioXCell BE0131 
Anti-mouse PD-L1 BioXCell BE0101 
Anti-mouse PD-1 Merck mDX400 
   
Chemicals, Peptides, and Recombinant Proteins 
Ruxolitinib  LC Laboratories R-6688 
Mouse interferon beta, carrier-free PBL Assay Science 12401-1 
Recombinant murine interferon gamma PeproTech 315-05 
   
Critical Commercial Assays 
IFN gamma ELISA Kit ThermoFisher 
Scientific 
KMC4022 
TruSeq Stranded Total RNA Library Prep Kit Illumina RS-122-2303 
Nextera DNA sample prep Illumina FC-121-1030 
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Antibody Concentration Kit Abcam Ab102778 
FITC Conjugation Kit Abcam Ab102884 
   
Deposited Data 
RNA and ATAC sequencing GEO GSE83850 
   
Experimental Models: Cell Lines   
Mouse: B16-F10 ATCC ATCC CRL-6475 
Mouse: TSA Laboratory of 
Sandra Demaria 
PMID: 19706802 
Mouse: 499, 237, 499 PDL1 KO  Laboratory of Andy 
Minn 
Mouse: JB2, all other CRISPR KO cell lines This paper N/A 
   
Experimental Models: Organisms/Strains   
Mouse: C57BL/6 Charles River 027 
Mouse: BALB/c Charles River 028 
Mouse: C57BL/6J The Jackson 
Laboratory 
00664 
Mouse: B6.129S7-Ifngtm1Ts/J The Jackson 
Laboratory 
002287 
   
Recombinant DNA   
N/A   
   
Sequence-Based Reagents 
See Table S1 for CRISPR/Cas9 gRNA Sequences:  This paper Table S1 
   
Software and Algorithms 
R language and environment for statistical 
computing and graphics 
https://www.r-
project.org 
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Bioconductor and packages https://www.biocon
ductor.org 
 
CRAN https://cran.r-
project.org/web/pa
ckages/ 
 
cutadapt https://pypi.python.
org/pypi/cutadapt 
 
STAR https://github.com/
alexdobin/STAR/re
leases 
 
Subread http://subread.sour
ceforge.net 
 
bowtie2 http://bowtie-
bio.sourceforge.ne
t/bowtie2/index.sht
ml 
 
Picard Tools https://broadinstitut
e.github.io/picard/ 
 
MACS2 https://pypi.python.o
rg/pypi/MACS2 
 
Wellington https://pypi.python.
org/pypi/pyDNase/
0.2.3 
 
FIMO http://meme-
suite.org/doc/fimo.
html 
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CRISPR Guide Information 
Sequence for gBlock containing 20 bp target size (N), U6 promoter, gRNA scaffold 
 and a termination signal. 
 
 
  
gBlock TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATCCG
GTACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATA
TTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGAC
TGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATT
TCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATAT
GCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTG
GAAAGGACGAAACACCGNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTA
GAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGG
CACCGAGTCGGTGCTTTTTTTCTAGACCCAGCTTTCTTGTACAAAGTTGG
CATTA 
PDL1 g1 GCTCCAAAGGACTTGTACGG 
PDL1 g2 ACTTGTACGTGGTGGAGTAG 
PDL1 g3 TATGGCAGCAACGTCACGAG 
STAT1 g1 GACTCCAAGTTCCTGGAGCG 
STAT1 g2 CAGCTGGACTCCAAGTTCCG 
STAT1 g3 TACGATGACAGTTTCCCCAG 
HVEM g1 GGGTCGGCACCCTGGAGCCG 
HVEM g2 CCTGAAGGTGTTGTCTGTAG 
HVEM g3 TCTGTAGGGGCCTGGCTCCG 
IFNAR g1 GGCGCGGCGGCCCTGGTGCG 
IFNAR g2 CTGGTGGCCGGGGCGCCTTG 
IFNGR g1 CCCGCAGGCGGCAGCTGGCG 
IFNGR g2 GTCCTGATGCTGTCTGCGAG 
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